

Mariano Bizzarri

Curriculum Vitae

Place: Roma
Date 12/10/1957

Part I – General Information

Full Name	Mariano Bizzarri
Date of Birth	12/10/1957
Place of Birth	Roma
Citizenship	Italian
	Full professor of Clinical Pathology
Spoken Languages	French, Italian, English, Spanish, Arabic, Portuguese
Orcid profile	0000-0003-0408-4136

Part II – Education

Type	Year	Institution	Notes (Degree, Experience)
University graduation	1981	La Sapienza	Master degree in Medicine and Surgery, 110/110 cum laude. Experimental Thesis: «biomarkers (mRNA) of pancreatic cancer». Supervisor: Prof. G. Fegiz.
Post-graduate Specialization	1986	La Sapienza	Attending Postgraduate Specialization in Oncology
Ph.D	1996 - 2000	La Sapienza	Ph.D in Experimental Surgery. Thesis title: «Inhibition of breast cancer cell growth upon melatonin and vitamin D3 treatment». Supervisor Prof. A. Cavallaro
National Scientific Qualification Licensure	2017	ASN 2017 ANVUR	National Scientific Qualification for Associate Professor for SC 06/A2 conferred by Italian National Agency for the Evaluation of Universities and Research Institutes

National Scientific Qualification Licensure	2017	ASN 2017 ANVUR	National Scientific Qualification for Full Professor for SC 06/A2 conferred by Italian National Agency for the Evaluation of Universities and Research Institutes
National Scientific Qualification Licensure	2017	ASN 2017 ANVUR	National Scientific Qualification for Associate Professor for SC 06/N1 conferred by Italian National Agency for the Evaluation of Universities and Research Institutes
Medical Licensure	1987	Qualification of the Medical Association	Ordine Medici Roma

Part III – Appointments

IIIA – Academic Appointments

Start	End	Institution	Position
1986	1987	Ente Fiuggi - Scholarship «Corrado Montemaggiori»	Bladder cancer research (Urologia, La Sapienza)
1999	2002	La Sapienza University	Contract professor on General and Organic Chemistry
2002	2021	La Sapienza University	Tenure track research assistant professor MED/05
2001	2004	La Sapienza University	Member of Administration Council (CdA Università La Sapienza)
2005	today	La Sapienza University	Head of the «Systems Biology Group Laboratory». Main topic: complexity of living organisms, OMIC technologies and Systems Biology. Management and supervision of several projects and PhD students, post-Doc
2022	Today	La Sapienza University	Associated Professor MED/05
2008	Today	Sapienza University of Rome – Interdepartmental Centre for Aerospace Research (CRAS)	Member of the Executive Board Committee
2012	2012	TUFT Medical School (BOSTON, MA, USA)	Lecturer on «microenvironment and cancer»
2011	2011	University of Tomsk (Russia)	Visiting Professor – Course on Systems Biology
2012	2014	Sapienza University of Rome	Appointed Teacher in the Ph.D Course in Biophysics
2014	Today	Sapienza University of Rome	Appointed Teacher in the Ph.D Course in Morphogenesis and Tissue Engineering
2015	2016	Blaise Pascal – Paris (France)	Advisor of the International Course on «organisms». Duties included lessons, seminars and participation in research investigations.

2014	2015	King Saud University (Saudi Arabia) – ISPP program - Dept. of Zoology (Prof. A. Halim Harrath)	Visiting professor. Duties included lessons, seminars and participation in research investigations.
2022	Today	Sapienza University of Rome	Appointed Member in the Scientific Committee of the Experimental Medicine department of “Sapienza Center for Research and Services Preclinical Experimentation and Animal Welfare” (SPBA)
2018	2019	King Saud University (Saudi Arabia) - ISPP program – Dept. of Zoology (Prof. A. Halim Harrath)	Visiting professor. Duties included lessons, seminars and participation in research investigations
2020	2020	La Sapienza University	Selection commission for n. 1 research grant category B, type II, SSD MED/05 - Codice procedura AR 15/2020 (rep. 445/2020, prot. 1694 del 28.9.2020)
2022	Today	MIUR	Scientific Expert - REPRISE
2024	Today	Space Biomedicine and Biotechnology Laboratory, promoted by the agreement between the University La Sapienza (Dept of Experimental Medicine) and Thales Alenia Space, the most relevant European Space Industry.	Head of the Laboratory. Main topic: theoretical basis of the interaction of microgravity with living organisms. Personalized Space Medicine. Food for Space. Shielding and counteracting strategies. Lunar and Mars habitat.
2024	2024	Sapienza University of Rome	President of the selection commission for the selective call procedure for n. 1 position associated professor at the Department of Experimental Medicine - Faculty of Medicine and Dentistry, for the Competition Sector 06/A2 - Scientific disciplinary sector MED/05

IIIB – Other Appointments

Start	End	Institution	Position
2001	2006	Ministero Politiche Agricole (MIPAF)	Member of the Scientific Committee of MIPAF
2001	2005	Ministero Politiche Agricole (MIPAF)	Member of the OGM Scientific Committee
2005	2014	ASI - Italian Space Agency	Appointed as member of the Scientific Committee of the Italian Space Agency
2006	2012	ASI - Italian Space Agency	Appointed as President of the Scientific Committee of TELESAL Program
2007	2008	ASI - Italian Space Agency	President of the Committee for promoting of New Technologies
2009	2010	ASI - Italian Space Agency	President of the Evaluation Commission of Human Spaceflight Missions
2010	2014	ASI - Italian Space Agency	Advisor of Telemedicine programs promoted by ASI
2010	2013	ASI - Italian Space Agency	ASI-CHINA Collaboration on the China Seismo Electromagnetic Satellite (CSES) project. Member of the evaluation committee

2011	2012	ASI - Italian Space Agency and CRUI - Conference of Rectors of Italian Universities	Member of the Joint internship committee for evaluation of post-doctoral students
2011	2014	ASI - Italian Space Agency	Appointed Coordinator of the Technology Transfer Unit of the Italian Space Agency
2012	2014	ASI - Italian Space Agency and ESA, European Space Agency	Advisor of the Human Spaceflight Programme (PB-HME)
2011	2014	ASI - Italian Space Agency	President of the Scientific Council of the Italian Space Agency
2013	2015	ASI - Italian Space Agency	Member Consulting Committee ASI for the assessment of Tor VERGATA University cooperation
2023	2023	MIMIT (Ministry of Business and Made in Italy)	Member of the selection committee, responsible for preparing the list of names to be proposed to the Minister for the appointment of the President of the Italian Space Agency (ASI).
2023	- today	Presidency of the Council of Ministers	Coordinator of the Technical-Scientific Table of COMINT (inter-ministerial committee for Space). The committee carries the task to elaborate the scientific and technological plan for the development of the Italian pipeline
2024	-	Ministry of Agriculture (MASAF)	Member of Scientific Committee of CREA (Council for Agricultural Research and Analysis of Agricultural Economics)

Part IVa – Research experience

year	Qualification	Institution	PROGRAM
1982-84	Pre-doctorate fellowship	National Institute of Tumors (Milan)	Member of FONCAM (task force against mammary cancer). Prof U. Veronesi director.
Pre-doctorate training	1982-1983	Perkin Elmer (Milan)	Course in HPLC
Pre-doctorate training	1982-1983	Perkin Elmer (Milan)	Course in Mass Spectrometry
1984 - 1993	Pre-doctorate fellowship	Dep.t of Chemistry (Prof. Aldo Laganà)	HPLC methods and protocols for investigating Hormones (Melatonin), amino acids (Tryptophan) and Antibiotics.
1996 - 2001	Ph.D student	Istituto I Clinica Chirurgica – La Sapienza	Endocrine control (melatonin, vitamin D3, Estrogens) on Breast Cancer growth
2002- today	Head of the Systems Biology Group Laboratory	Dep.t of Experimental Medicine – La Sapienza	Main topic of investigation: a) role of biophysical force in cell phenotypic commitment; b) Space Biomedicine; c) Endocrine control in cell differentiation.

2003-2008	Co-Principal Investigator	In cooperation with Chemistry-Physics Chair (Dep.t of Chemistry, Prof. Filippo Conti) and the ASSIMET research association	I carried out several studies with Prof. F. Conti on Metabolomics and cancer. Studies were applied according to a translational approach in investigating the metabonomic profile of cancer patients (in cooperation with Prof. F. Di Silverio and prof. R. Passariello).
2009-2010	Scientific Advisor	ASI (Italian Space Agency)	Space Research Program (PTA 2009-2011) of the Italian Space Agency
2013 - 2017	Scientific Director	KOSMOMED – ASI (Italian Space Agency)	KOSMOMED – ASI (Italian Space Agency) Program. I planned the development of an integrated telemedicine program (KOSMOMED), involving as many as 20 research groups from different Italian Universities, under the supervision of ASI and in cooperation with Kell company. A pilot experimentation was performed in the town of Anzio, involving patients, medical doctors, pharmacists and many Clinical centres as well as the Italian Space Agency (ASI)
2015-2019	VQR (2015-2019)	ANVUR	Result: Excellent
2021	Head of the Joint Research Groups	Azienda Ospedaliera “Ospedali Riuniti Marche Nord” – La Sapienza	I planned the investigation focused on the Modulation of the inflammatory response and the release of cytokine il-6 in lymphocytes of patients affected by covid-19
2024	Head of the Laboratory	Space Biomedicine and Biotechnology Laboratory, promoted by the agreement between the University La Sapienza (Dept of Experimental Medicine) and Thales Alenia Space, the most relevant European Space Industry.	I am the Head of the Laboratory. Main topic: theoretical basis of the interaction of microgravity with living organisms. Personalized Space Medicine. Food for Space. Shielding and counteracting strategies. Lunar and Mars habitat. However, the lab program included also an educational perspective, with the recruitment of three Ph.D students, involved in industry/University partnership.

Part IVb – Teaching experience

Year	Institution	Lecture/Course
1999 - 2001	University La Sapienza	Contract professor in General and Organic Chemistry – Teaching assignment in Chemistry for Laboratory Technicians – 2 CFU

2001-2002	University La Sapienza – Rieti - Medical Radiology and Radiotherapy Technicians	Teaching assignment in Biochemistry course – 2 CFU
2001-2011	University La Sapienza - Course for Laboratory Technicians	Teaching assignment in General and Organic Chemistry course - 2 CFU
2003-2009	University La Sapienza	Teaching assignment in Clinical Pathology in the School of Specialization in Oncology – II. 2 CFU
2005-2006	University La Sapienza - Latina	Teaching assignment in «LABORATORY MEDICINE and CLINICAL PATHOLOGY», Degree in Medicine and Surgery CCLM-E, 1 CFU in MED/05
2005-2010	Università La Sapienza – Rieti - Medical Radiology and Radiotherapy Technicians	Teaching assignment in Biochemistry – 1 CFU; and General and Organic Chemistry 2 CFU
2007-2012	Università La Sapienza - sede di Rieti - Laboratory Technicians	Teaching assignment General and Organic Chemistry course – 2 CFU
2024 - today	Università La Sapienza	32365 - Teaching assignment in the Master degree in Dentistry and Dental Prosthodontics - Degree in Medicine and Surgery Clinical Pathology, 2 CFU in MED/05
2013-today	University La Sapienza - Medicine and surgery "D"	30896 - Teaching assignment in Clinical Pathology in the Course of «LABORATORY MEDICINE and CLINICAL PATHOLOGY», Degree in Medicine and Surgery CCLM-D, 6 CFU in MED/05
2022-today	30005 Sciences of diagnostic technical health professions - Degree course A - Rome Company Policlinico Umberto I LM/SNT3	Teaching assignment in Clinical Pathology MED/05 – 2 CFU
2022-today	29997 Biomedical laboratory techniques (qualifying the healthcare profession of biomedical laboratory technician) - Degree course A - Rome Policlinico Umberto I L/SNT3	Teaching assignment in Clinical Pathology MED/05 – 2 CFU
2020 - today	Università La Sapienza - Medicine and surgery "A"	30891 - Course of «LABORATORY MEDICINE and CLINICAL PATHOLOGY», Degree in Medicine and Surgery CCLM-A, 2 CFU in MED/05
2021 – today	Università La Sapienza - Medicine and surgery "B"	30894 - Course of «LABORATORY MEDICINE and CLINICAL PATHOLOGY», Degree in Medicine and Surgery CCLM-B, 4 CFU in MED/05
		Current teaching load: 18 CFU
20-30 Sept. 2007	Institute of Nutrition and food safety – Cuba (University of LA Habana)	Teaching assignment in the course of «General Pathology. Nutrition and Cancer»
29-30 March 2011	ASI (Italian Space Agency) - ALTEC (Aerospace Logistics Technology Engineering Company)	Teaching assignment in the Master Course in Space Biomedicine (Turin)
2010	University «G. D'Annunzio» - Chieti-Pescara	Member of the Evaluating Committee in Ph. D in Muscle Biochemistry and Physiology - XXI-XXII cycle
1 March – 31 May 2014	Università La Sapienza – VIII Winter School on Geopolitics	Teaching assignment in Space Technologies Course
2014-15	ENS - Chaires internationales de recherche Blaise Pascal	External reviewer of the Blaise Pascal Teaching Program
7-10 June 2017	University of Alcatraz (Perugia) and Chieti-Pescara	Teaching assignment in the Course: Methods and Limitations of biological research in Space
22-26 January 2017	Winter School - Springer	Frontiers in Gynecological Endocrinology. Pre-Menopause, Menopause and beyond: Clinical Problems and Practical solutions

2016-17	University La Sapienza	Second level Master's degree in "Clinical research: methodology, pharmaco-vigilance, legal and regulatory aspects"
2017-18	University La Sapienza	II Level Master in Clinical Research. Methodology, pharmaco-vigilance, legal and regulatory aspects
2018-2019	University Suor Orsola Benincasa	Teaching assignment in the Course: Systems biology approach to cancer: fractals, attractors, and nonlinear dynamics
2011-12	Ph.D in Biophysics – La Sapienza	Seminar: Systems Biology and Human Pathology
5-9 Sept. 2011	Tomsk State University	Teaching assignment in International Scientific School on promising directions in Biophysics and Biotechnology
9 April 2009	MASTER I LEVEL Gastronomic sciences and food pathologies – La Sapienza - Rieti	Seminar: «Transgenic foods»
23-25 Nov 2009	Università La Sapienza – Chemistry Dept.	Seminars on «General Pathology of Carcinogenesis»
6-9 Dec. 2010	Università La Sapienza – Chemistry Dept.	Seminars on «General Pathology of Carcinogenesis»
2012	ASI Italian Space Agency	Seminar: «Magnetic screens for interplanetary travel»
27-29 Feb. 2012	REGIONAL SCHOOL OF GYNECOLOGICAL ENDOCRINOLOGY – Messina University	Seminar: «Inositol in PCOS»
14/7 2020	Ospedali Riuniti Marche Nord	Seminar: «Science at the bed of COVID patient»
9 May 2024	Sapienza School for Advanced Studies –SSAS	Seminar: «Human body and cosmos: space biomedicine»
2024-25	UNITELMA (Sapienza University)	Master (I level) in: CARDIORESPIRATORY REHABILITATION AND DIGITAL HEALTH FOR MEDICAL-HEALTH PROFESSIONS. Teacher of Biomedical Space Technologies

Part IVc International Research Cooperation

2007-2012	Departamento de Bioquímica y Fisiología – University de la Habana	I established a fruitful working cooperation that was finalized to several papers dealing with Entropy and metabolism in cancer cells. Moreover, we extended our investigations on Macrobiotics, Nutrients and Cancer
2008-2014	TUFT Medical School – Boston (MA, USA) – under the supervision of Prof. Ana Soto and Carlos Sonnenschein	The role of the microenvironment on Cancer represented the principal focus of a number of studies (developed in Boston as well as in my Lab in Rome), seminars and meetings. The cooperation led to the publication of articles in the field. Furthermore, this cooperation paved the way for the birth of the journal <i>Organisms</i> – in which American colleagues were included as members of the Editorial Board – and the organization in Rome (2017) of the International Meeting «where are biological sciences going»
2008 – 2019	Polytechnique of PERM and TOMSK (Russia) – in cooperation with prof. Oleg Naimark	The cooperation focuses in debating the biophysical aspect of cancer biology. I held several seminars during specific courses (in 2008 and 2019), and participated in two international meeting organized in Siberia. The cooperation led to the publication of several joint papers.
2020-today	EGOI - The Experts Group on Inositol in Basic and Clinical Research, and on PCOS (EGOI-PCOS)	I participated in planning shared experiments that eventually end up in the publication of many papers and in the organization of international meetings and specific specialist courses, in Italy as well as in Europe. Specifically, I set the first in vitro/in vivo experiment demonstrating that aromatase is severely downregulated in PCOS and can be re-activated by myo-Inositol. EGOI was established to explore and elucidate key aspects of the physiological functions and clinical applications of Inositols across various biological and medical

2019-2021	King Saud University, Riyadh (Saudi Arabia) – University La Sapienza, Rome, Italy	disciplines, with a particular focus on gynecology, reproduction, and metabolic-endocrinological disorders.
2022-today	King Saud University, Riyadh (Saudi Arabia) – University La Sapienza, Rome, Italy - Laval University, Québec, Canada.	Definition of joint Research programs. Microenvironment and cancer reversion. I supervised and participated in two research program during the visiting professor period
2022-today	Laboratory for Molecular Cell Biology – University College London (Prof. A. Saiardi)	I actively participated in planning an integrated research program alongside with representative of KSU (Saudi Arabia) and Laval (Quebec) Universities. Submission of the project «Interplay of ion channels-based activity, membrane trafficking, and membrane lipids in cell fate commitment in cancer biology» has been performed. The proposal has passed the first evaluation phase and it is under scrutiny for the final step
2022-today	Laboratory for Molecular Cell Biology – University College London (Prof. A. Saiardi)	I am participating with prof A. Saiardi in planning an investigation on the physiology and molecular biology of Inositol and related pyrophosphates. The research program is jointly ongoing, by sharing respective co-workers.

Part IVd – Institutional Commitments

2005-6	Committee for investigating Health Effects of Low Electromagnetic Field – Provincia di Roma	Member of the committee with the task to made a survey regarding the health effects of ELF (low electromagnetic fields). Scientific report on: Biological effects of electromagnetic fields low frequency (ELF)
2007-8	Committee for the evaluation of scientific and technological strategies – Italian Parliament	Member of the Committee, Scientific report on Space Biotechnologies and Biomedicine. I participated in writing several reports, specifically pointing out the contribution of Space Technologies.
2010-11	COPIT (parliamentary committee for technological innovation and sustainable development) – Italian Parliament	Invited member for scientific analysis. I specifically provided Telemedicine reports.
2009-2011	TELEA Program - ASI	Telemedicine program for AFRICA (TELEA, Kenya) – I was the head of the Technological program, with the task to elaborate a number of technological plans for civil using of space technologies and telemedicine support. I developed an integrated project involving Universities and Industrial stakeholders.
2021-today	PNRR program on Space Research	Appointed as Sapienza University advisor for PE15 Spoke 9 (Space Biomedicine & Habitat). Responsible for the planning of an integrated program of space biomedicine. Approved by ASI (Italian Space Agency)
2023	President of the Polish Republic	Awarded as member of the Polish Academy of Sciences – Nicola Copernicus. Appointed member of the Medical Section.
2023	Senate Joint Committees on Agriculture	Appointed as speaker for investigating the reliability of and safety of synthetic meat. Written report submitted as a technical basis for the endorsement of Parliament law.
2023	Presidency of the Council of Ministers	Coordinator of the Technical-Scientific Table of COMINT (inter-ministerial committee for Space). The committee carries the task to elaborate the scientific and technological plan for the development of the Italian pipeline. I directly participated in writing documents and reports dealing with those topics.

Part V - Society memberships, Awards, and Honors

Year	Title
1983	Knight of the Holy Cross of Jerusalem (Patriarch Maximos V) – for organizing the Cancer Research Institute on the behalf of the Greek-Melkite Church (Syria)
1991	National Award for Scientific dissemination (independent association for journalism) - Rome
2002	City of Rome Award for Scientific Results
2008	Giovanni Alfonso Borelli Medal – awarded by Naples (Medicine University)
2006-2014	General secretary - Italian Society for Space Biomedicine and Biotechnology
2012	XIV edition of the National Culture Award «Altipiani di Arcinazzo»
2009 - 2014	Editor in Chief of <i>Space Magazine</i> (ASI Ed.)
2018-today	General Secretary and Treasurer Waspalm (World Association of Societies of Pathology and Laboratory Medicine)
2016-today	Member of SIPMEL (Società Italiana di Patologia Clinica e Medicina di Laboratorio)
2017	European Award for Science: Bibliothèque Solvay conference cycles (European Commission - «Edificio»)
2018	Appointed to the Honorary Committee of the “Lomonosov” Institute of Chemistry of the University of La Habana (Cuba) (Rectoral Decree 784/2018)
2020	International Golden Eagle Award (for research on the inflammatory pathways triggered by Sars-CoV2) – awarded by Abruzzo Region
2012	Editorial board of Biophysics and Bioengineering Letters (La Sapienza Ed.) ISSN 2037-0199
2012	Editorial Board of the <i>International journal of safety and security engineering</i> ISSN: 2041-9031
2017	Editor in chief of “ORGANISMS journal of Biological Sciences” (La Sapienza Ed.) ISSN: 2532-5876
2017	Associated Editor of <i>Cancer Cell International</i> ISSN 1475-2867
2022	Editorial Board of <i>Academia Biology</i> ISSN :2837-4010
2022	Editorial Board of <i>Cells</i> ISSN 2073-4409

Part VI - Funding Information [grants as PI-principal investigator or I-investigator]

Year	Title	Program	Grant value
2006-2010	Scientific Direction	TELESAL (ASI). The program was conceived to establish a technological platform supporting the transmission of huge data (including images, and to coordinate preliminary medical experimentations. The architecture of the plan and the objectives related to medical studies relied on my personal expertise. Universities and Scientific Centres (IRCSS) were involved in the program developed by Kell company under the supervision of ASI (Italian Space Agency). I supervised the realization of different sub-programs, as well as their test during pilot experimentation.	4.500.000,00 E
2008-2010	Co-Principal Investigator	VANSUT (MIPAF, Ministry of Agriculture) Pro-apoptotic activity and modulation of the neoplastic cell cycle of polyphenols and flavonoids. The project was funded by	28.000,00 E

		the Italian Ministry of Agriculture and allowed the publication of five peer-reviewed papers.	
2010-2012	Principal Investigator	LIGRA (Life in Gravity) (supported by the Italian Space Agency, ASI). The project focused principally at ascertaining the theoretical basis of the interplay between living systems and gravity. The program was followed by the publication of four peer-reviewed papers.	300.000,00 E
2010-2013	Co-Principal Investigator	COSISBY (supported by ASI, Italian Space Agency) was a program developed by the Dept of Experimental medicine, La Sapienza University. The project focused on a number of critical molecular pathways de-regulated in microgravity conditions,	300.000,00 E
2009-2011	Principal Investigator	Cooperation (ASI) Italian Space Agency-Sapienza. I supported the development of Biomedical programs by ASI, namely those finalized in providing a Telemedicine support for medical activities in emergency situations and/or undeveloped countries	60.000,00 E
2012	Principal Investigator	Liberal donation – TELESPAZIO – Project n. 000055.	10.000,00 E
2013-2017	I – Scientific Direction	KOSMOMED – ASI (Italian Space Agency) Program. I planned the development of an integrated telemedicine program (KOSMOMED), involving as many as 20 research groups from different Italian Universities, under the supervision of ASI and in cooperation with Kell company. A pilot experimentation was performed in the town of Anzio, involving patients, medical doctors, pharmacists and many Clinical centres as well as the Italian Space Agency (ASI)	4.000.000, 0 E
2014-2018	Principal Investigator	National Network for Pain Therapy -Università Sapienza - Policlinico Umberto I - DELIBERA n. prot. 27479 del Policlinico Umberto I del 30/07/2014	118.000,00 E
2013-2016	Principal Investigator	Maternal morphogenetic fields and in vitro and in vivo cancerous reversion of breast cancer cells - FONDAZIONE ROMA project. n. M_000055_12 – Grant n. 8.1.3.3.19.1	57.000,00 E
2015-2018	Principal Investigator	MISSIONE FUTURA 2015-2018 – Project CYTOSPACE – ASI. I directly planned the first experiment to assess cytoskeleton changes in real microgravity. The experimentation was performed with the collaboration of Samantha Cristoforetti, Italian astronaut. Results are in press.	300.000,00 E
2019	Principal Investigator	ABOCA - liberal donation. Study for non-canonical pharmacodynamics of herbs	30.000,00 E
2020-21	Co- Principal Investigator	- ATENEO – Project n. RM120172A840E501 - In vitro and in vivo antitumor effects of treatment with the proteasome inhibitor Bortezomib in malignant mesothelioma (in cooperation with Prof. Laura Masuelli)	25.000,00 E
2021	Principal Investigator	Stem cell and tumor extracts - - Aurora Bioresearch – liberal donation	30.000,00 E
2022	Principal Investigator -	Analytical determination of biomarkers of tissue damage - ATENEO – Project n. RM1221816163F0DC - MUSCOLINO	10.000,00 E

2023	Principal Investigator –	ATENEO – Project n. RG123188AEFD2C0D - BABYBOOM program. Modulation of steroidogenic activity in 3D coltures of ovaries and granulosa/theca cells under microgravity condition. Role of inositol in counteracting steroidogenesis imbalance	24.000,00 E
2022- today	Principal Investigator –	Ovospace – MISSIONE MINERVA 2022-2024. ASI project 000055_22_PNP_BIZZARRI_Ovospace. I planned the first experiment in real weightlessness to assess ovarian steroidogenesis and its impact upon fertility. Results are ongoing to be submitted	300.000,00 E
2023 - today	Co- Principal Investigator	Project GRAVICUORE. ASI– project n. DC-DSR-UCO-2023-16. I am heading the section dealing with the discovery of novel biomarker of muscle/cardiac damage released by cells/tissues exposed to microgravity. Results will be translated into clinic to ascertain their usefulness and salivary markers for application in clinical settings as well as for diagnosis in space (astronauts).	300.000,00 E
2023- topday	Principal Investigator –	Orion – MISSION-Ax-3. ASI project n. CUP F85F21006260005. The program focuses on pharmacological measures to counteract steroidogenesis imbalance induced by microgravity exposure upon ovary cells. The experiment was performed with the collaboration of Lt Col. Walter Villadei, Italian astronaut.	80.000,00 E
2023-24	Principal Investigator	La Sapienza - FUNDS FOR CONFERENCES, CONFERENCES AND WORKSHOPS - DD n.3841/2023. The meeting will provide preliminary results regarding findings obtained in the PNRR program (PE15 Spoke-9)	1.500,00 E
2023	Principal Investigator	PNRR – PE15 – Spoke. Already approved by ASI – under La Sapienza evaluation	650.000,00 E

Part VII – Research Activities

Keywords

Brief Description

Systems Biology and Complex systems - microRNAs	<p><i>Complex systems and tumor reversion.</i> Integrated analysis at the biophysical and molecular level of the interactions between cells and the microenvironment, with particular reference to the evaluation of phase transitions described by non-equilibrium thermodynamics constituted a topic actively pursued since the beginning of my research activities. Identification of transition markers and their use in the translational field as clinical markers are ongoing (Semin Cancer Biol. 2011, 21(3):175-82. doi: 10.1016/j.semcancer.2011.04.002). Study of regenerative processes occurring during these phase transition were finalized in investigating the phenomenon of tumor reversion. This approach has led to identify a) quantitative (fractal) parameters of cell phase transition, specifically by identifying the acquisition of tumor cell resistance (Cell Adh Migr. 2013 Sep 1;7(5):450-9. DOI: 10.4161/cam.26765), the reversion of the cancer phenotype (Semin Cancer Biol. 2022 Feb;79:83-90. doi: 10.1016/j.semcancer.2020.09.005. PMID: 32920125.), and eventually the usefulness of fractal parameters in differentiating benign from malignant tumors of the breast. Moreover, these studies allowed in recognizing specific hallmarks of cancer reversion (Cancers (Basel). 2023 doi: 10.3390/cancers15082317). The molecular mechanisms supporting the process of tumor</p>
Microgravity	
Analytical sensors and Space Biomedicine	
Analytical methods	
Endocrine control and Inositol molecular biology	
Anticancer effect of melatonin, inositol, and grape seed extract	

reversion – induced by drugs or eggs/fish extracts have been partly elucidated, namely by identifying some microRNAs that exert specific epigenetic control over genome expression (Cancer Lett. 2021 doi: 10.1016/j.canlet.2021.07.001.). These results have been instrumental in performing translational studies. We obtain a patent related to the extract obtained from embryo fish and this formula has been tested in several randomized, multicentric clinical trials (Oncol. Res. 2005, DOI: 10.3727/096504005776449716; Cancers (Basel). 2023. doi: 10.3390/cancers15102809). Clinical results were highly promising and are currently under scrutiny in a larger randomized trial carried out in cooperation with Humanitas Hospital (Milan). These results enabled also the publication of several papers dealing with the subject of complexity in biological systems (Front Physiol. 2019 Jul 26;10:924. doi: 10.3389/fphys.2019.00924; Int. J. Mol. Sci. 2023, 24, 11603. doi.org/10.3390/ijms241411603; Entropy 2020, 22(8), 885; doi.org/10.3390/e22080885; Prog Biophys Mol Biol. 2013, 112(1-2):33-43. DOI: 10.1016/j.pbiomolbio.2013.03.019). Finally, results obtained in vitro and in vivo allowed to obtain two international patents related to the identified anti-cancer compounds (Pat. # A61K 35/60 n. WO 2007/020222 A2; and #102021000030629 - 8/1/2024). Studio dei processi di determinazione fenotipica e di differenziamento nel corso delle prime fasi dello sviluppo (oocita in pazienti affette da sindrome dell'ovaio policistico) e in presenza di patologie degenerative (neoplasie). Differenziamento cellulare e tissutale come paradigma di transizione di fase

Microgravity. The gravitational field has played a major role in shaping evolution when life moved from water to land. However, gravity may influence in a more deep and subtle fashion the way the cells behave and build themselves. Cells may indeed 'sense' changes in the microgravity field through (1) an indirect mechanism (mainly based on the modification of physical properties of their microenvironment); (b) the development of specialized structures for the mechanical perception and transduction of gravitational forces (like the cytoskeleton); (c) changes in the dynamics of enzymes kinetics or protein network self-assembly. I have addressed those issues in a number of papers providing for the first time a theoretical hypothesis based on the non-equilibrium thermodynamics (Nature microgravity, 2019 Nov 21;5:27. doi: 10.1038/s41526-019-0088-x; Bioessays. 2018 Jan;40(1). doi: 10.1002/bies.201700138). Briefly, loss of the gravitational constraints enabled the cell population to split spontaneously into two different phenotypes, highlighting how a same genotype can sustain more than one phenotype. Furthermore, I evidenced how critical pathways (including apoptosis) work in microgravity, affecting in different ways normal and cancerous cells. Experiments performed either in real (on board of the International Station, Mission Minerva – Cytospace project - with Samantha Cristoforetti) or simulated microgravity demonstrated that the cytoskeleton plays a pivotal role in transducing gravity effects upon cell physiology (Int J Mol Sci. 2021 Jan 16;22(2):862. doi: 10.3390/ijms22020862. PMID: 33467082).

Analytical sensors and Space Biomedicine. The need to develop wearable sensors and systems capable of detecting a useful set of parameters of physiological interest constitutes a critical need for the purposes of human space exploration and colonization of the Moon in the context of identifying new markers of muscle and cardiac damage (Anal Bioanal Chem. 2008, 391(5):1969-76. PMID:18421442). I developed – in cooperation with the Faculty of Engineering (University of Tor Vergata) a number of devices for the detection of analytes in salivary samples (Sensors (Basel). 2013 Dec 4;13(12):16625-40. PMID: 24304640 PMID: PMC3892864 DOI: 10.3390/s131216625), as well as augmented reality applications to support the crew in the correct use of sensors for diagnostics (AEROSPACE SCIENCE AND TECHNOLOGY, 2014, 39: 666-674, ISSN: 1270-9638, doi: 10.1016/j.ast.2014.05.018). An omic approach has also been investigated to record biochemical changes occurring during a prolonged, simulated exposure to a the Martian environment (Chromatographia 2011, 73 (suppl. 1): 45-53, DOI: 10.1007/s10337-010-1880-7). I am currently involved in an international program (MILONE), ruled by our lab with Polytechnique of Bari and NASA to construct an integrated teranostica suit for astronauts.

Analytical methods. I have performed a number of HPLC analytical protocols – with MS/UV detection – for the integrated analysis of Tryptophan and metabolites (Biomed Chromatogr. 1990, 4 (1):24-7. PMID: 2310838), antibiotics (Biomed Chromatogr. 1990, 4 (5):205-7. PMID: 2279147), circulating tumor markers (Anticancer Res. 1995, 15(5B):2341-6. PMID: 8572649), and noticeably for the assessment of the entire spectrum of sex steroids hormones (submitted). I also performed the first HPLC method for the assay of Melatonin in serum (Anal. Chim. Acta, 1995, 316: 377–385 doi: 10.1016/0003-2670(95)00298).

Endocrine control and Inositol molecular biology. Studies of the developmental dynamics points primarily on early oocyte/embryo differentiating processes occurring during the early life stages. I investigated those pathways involved in oocyte maturation (namely those involving steroidogenesis) by pointing out how changes in the overall cytoskeleton organization and in the oocyte/microenvironment cross talk can efficiently modulate oocyte maturation (J Cell Physiol. 2018 Oct 14. doi: 10.1002/jcp.27623). To address these issues I have used both 2D-3D-models as well as rodents. The modulatory role of natural pharmacological compounds (like inositol, melatonin and α -lipoic acid) has been studied to demonstrate how such nutraceutical manipulation can improve and regulate the first steps of the morphogenetic process (Expert Opin Drug Metab Toxicol. 2020, 16(3):255-274. doi: 10.1080/17425255.2020.1737675). A central field of investigation is represented by studies focusing upon the endocrine control of ovarian and breast cells (Cells, 2024). Furthermore, the potential utility of such compounds in treatment of infertility disorders (like Polycystic Ovary Syndrome) is the subject of intensive research both in vitro and in vivo, through a wide international cooperation (Int J Mol Sci. 2021; 22(19):10575. doi: 10.3390/ijms221910575).

Anticancer effect of melatonin, inositol, and grape seed extract. I performed several studies in order to assess the anticancer properties of natural compounds, including Melatonin (J Pineal Res. 2018 Jan 16. doi: 10.1111/jpi.12467), myo-Inositol (Exp Cell Res. 2016 DOI: 10.1016/j.yexcr.2016.05.007) and Grape seed extracts (epigallocatechin, procyanidins) (Br J Nutr. 2013, 110(5): 797-809. DOI: 10.1017/S0007114512006095.). Those studies allowed identifying their pro-apoptotic effects as well as the modifications induced on a number of critical pathways through non-canonical mechanisms (Drug Discov. Today. 2020, S1359-6446(20)30080-5. doi: 10.1016/j.drudis.2020.02.010).

Part VIIb– International Institutional Cooperation activities

2004	Advisor of the project on Melatonin's Founding Research and Policy Division (Health Research Board Ireland).
2009-2010	ASI-ISRAEL scientific cooperation. Member of the joint committee between the Italian Space Agency and Israel government
2011	Reviewer of Patent Commission - BSP-RPRM-2011-4 (Bentham Science Publishers)
2015	External Reviewer in evaluating Tenure candidate from KSU (King Saud University) - BADR ABDULLAH ALDAHMAH
2017	External Reviewer in evaluating Tenure candidate from KSU (King Saud University) - Abdelhabib Semlali
2017-2018	External Reviewer in evaluating the research proposal n. 2017 Nov PhD 1041 - Breast Cancer Now PROGRAMME (UK)
2020	External Reviewer in evaluating Tenure candidate from KSU (King Saud University) - Suliman Alomar
2021 -today	Polish Ministry of Education – member of the Educational Programs Committee
2021 - today	ITALY-POLAND agreement for Scientific Research – Member of the Joint Committee (signed agreement in Rome in between the Experimental Medicine Dept. (La Sapienza) and Polish Universities)

2021-today	Member of the joint committee between the Medical Research Agency of Poland and La Sapienza University – Sobieski Research Program
2023-2024	Swiss National Science Foundation – Evaluation Committee of Research projects
2024 - today	MILONE Project – ASI, La Sapienza, Italian Aerospace Armed Force, Polytechnique of Bari. Oklahoma University and NASA. This is the first teranostic device, which provide diagnostic insights while performing a therapeutic stimulation to overcome microgravity-induced distress on muscle performance. I have the task to associate sensor-based analysis for recognizing endocrine and molecular parameters.

Part VIIc- Reviewer for National and International Journals

- Editor in chief of *Organisms* (La Sapienza Ed.).
- Associated editor of *Cancer cell International*; Member of Editorial Board of *Cells*; *Academia Biology*.
- Ad Hoc Reviewer for international peer-reviewed journals: *J of Medicinal Foods*; *International Journal of Molecular Sciences*; *J of Spectroscopy*; *Journal of Cellular Physiology*; *Apoptosis*; *Cancers*; *Acta Astronautica*; *Biomedicines*; *Human Cell*; *Biomicrofluidic J.*; *Biomed Pharm*; *Gynec Oncol*; *Cancer Res.*; *Sci Rep.*; *Frontiers in Cell and Developmental Biology*; *Cells*; *Am J Pathol.*; *Biophys. J.*; *Molecules*; *NpJ Nature*; *Virus*; *Nature Comm.*; *Autophagy*; *J Ovary Res.*; *Mol Cancer*; *Frontiers in Oncol.*; *Exper Med Ther.*; *Int H Endocr. Rev.*; *Cell Biol Int.*; *Biomed Pharmacoth.*; *Eur J. Med Plant*; *BMC mol Biol.*; *Cancer Biomarkers*; *Asian Pac J Trop Med.*; *Human Repr.*; *JPR*; *Progr Biop Mol Biol.*; *Oncotargets*; *Physica A*; *J Cell Death*; *Phytomed.*; *Int J Endocr.*; *Food Function*; *Curr Pharm Des*; *Cell Physiol. Biochem.*; *Biomed Res.*; *BMC Arthritis*; *BMC Compl Alter Ther.*; *J Theor Applied Vasc Res.*; *Toxins*; *Br J Pharmacol.*; *Cell Mol Life Sci.*; *Reg Med Res.*; *Drug Des.*; *Cell Death Diff.*; *J Appl. Med.*; *J Bas Appl Res Int.*; *Integr. Med.*; *Bioinform.*; *Coimbinat. Sci.*; *JNCI*; *ISKAS*; *J Biosci.*; *Front. Physiol.*; *Gastroent Res Pract.*; *CAM*; *Cell Mol Biol.*; *Biofactors*; *JNCI Cancer Theory*; *Theory in Biosc.*; *Oncol discovery*; *Cell prolifer.*; *Curr. Metab.*; *Biosystems*; *Ann of Oncol.*; *Acta oncol.*

Part VIId-Supervision of Graduate Student and Postdoctoral Fellows

Tutoring and coordination of the scientific activities of students, PhD students, postgraduates and undergraduate students

- R. F. Medicine and Surgery – Master degree (La Sapienza) – 2003-2009
- T I. Master specialization in Oncology (II School of La Sapienza) – 2004-05
- B. V. Master scienze gastronomiche e patologie alimentari (La Sapienza) 2008-09
- P. B. Master scienze gastronomiche e patologie alimentari (La Sapienza) – 2008-09
- E. L. Master degree in biology – Faculty of sciences Roma III - 2009-10
- S. P. Ph.D in Morphogenesis and Tissue Engineering (La Sapienza) – 2009-2011
- MG M. Master degree in medical biotechnologies (La Sapienza) 2011-2012
- A. P. Ph.D in Basic and Applied Medical Sciences (Università de L'Aquila) – 2010- 2012
- G. di D. Master degree in Medical Radiology and Imaging Techniques (La Sapienza) – 2011-12
- F. T. Medicine and Surgery – Master degree (La Sapienza) - 2009 -2012
- S. D. Ph.D Course in Experimental Medicine (La Sapienza) - 2010-2013
- E. P. Medicine and Surgery – Master degree (La Sapienza) - 2012–2015
- M. G. M. Ph.D Course in Experimental Medicine (La Sapienza) - 2012-2015
- S. D. Pharmacy and Medicine Degree (La Sapienza) - 2016-2017
- M. M. Genetics and Molecular Biology Master Degree (La Sapienza) – 2016-2017
- G. F. Pharmacy Master Degree (La Sapienza) – 2016–2018
- G. V. Ph.D in Morphogenesis and Tissue Engineering (La Sapienza) – 2015-2018
- M. M. Ph.D course in Morphogenesis and Tissue Engineering (La Sapienza) – 2018-2021
- G. P. Master degree in Medicine and Surgery (University of Perugia) 2018-19.
- A. S. Medical Biotechnologies (La Sapienza) - 2018-2020
- N. M. Ph.D course in Morphogenesis and Tissue Engineering (La Sapienza) – 2020-2023
- A. Q. Genetics and Molecular Biology degree (La Sapienza) – 2020-2022
- A. Q. PhD course in Morphogenesis and Tissue Engineering (La Sapienza) – 2023 – today
- G. L. Medical Biotechnologies Degree (La Sapienza) – 2022-2023

- F. G. Master (II level) in Clinical research and Medical Affairs (La Sapienza) – 2022-2023
 A. P. PhD Course in Science and Engineering for Man and the Environment (Campus Biomedico Roma) – 2020-2022
 V. F. PhD course in Morphogenesis and Tissue Engineering (La Sapienza) – 2021-2023
 R. D. Master (II level) in Clinical research and Medical Affairs (La Sapienza) – 2022-2023
 G. L. Ph.D Course in Biology and Molecular Medicine – 2023 today
 A. P. Ph.D in Molecular Medicine (La Sapienza) – 2023 today
 G. C. PhD course in Morphogenesis and Tissue Engineering (La Sapienza) -2024
 E. L. Space Engineering Master degree 2022 (La Sapienza) – today.

Part VIIe – Activities of the Third Mission

PROJECT “PNRR -NEXT GENERATION ORIENTATION EX D.M. 934/22 (2022) (Seminars in Secondary Schools)

Part VIII – Summary of Scientific Achievements

International peer-reviewed papers: 58.8% of the articles are in the top 25% journals by CiteScore (Scopus).

Authorship: first and last author in 63% of papers (Scopus)

The international cooperation took place in 37% of the published papers

Product type	Number	Data Base	Start	End
Papers [international] peer-reviewed	179	Scopus	1991	2024
Papers [national]	25		1983	2024
Books (English) [scientific] international	4	Scopus	2012	2023
Books [teaching]	2		1998	2020
Books (Italian)	6		1991	2022
Books (Spanish, Portuguese)	2		2001	2010
Patent	A61K 35/60 International publication number n. WO 2007/020222 A2	International Patent Anticancer protein extracted from Zebrafish embryo. Int. publication date: 22/02/2007	2007	2027
Patent	n. brevetto 0001400147 - 102010901819782 del 17/09/2011. Supported by La Sapienza University	Morphogenetic fields in cancer	2011	2021
Patent	Released by MIMIT (Ministry of Business and Made in Italy) N. - 102021000030629 del 8/1/2024	Anticancer molecules. In cooperation (50%) with Aurora Bioresearch	2024	2034

Total Impact factor	751,49
Total Citations	4816
Average Citations per Product	27
Hirsch (H) index	41
Normalized H index*	1,3

*H index divided by the academic seniority.

ANVUR indicators for Full Professor-PO

Personal Value	Threshold Full Professor-PO	Threshold evaluation experts
111	21 number of articles	33 number of articles
4587	743 citations number	2108 citations number
37	15 H-index last 15 years	24 H-index last 15 years

Part IX– Selected Publications

List of the publications selected for the evaluation. For each publication report title, authors, reference data, journal IF (calculated according to the publication year), citations, and authorships (first/last and corresponding name).

N	Authorship	Title, Authors, Journal, Year, DOI	IF (publication year)	citations	Corresponding name
1	Last name	Monti N, Dinicola S, Querqui A, Fabrizi G, Fedeli V, Gesualdi L, Catizone A, Unfer V, Bizzarri M. Myo-Inositol Reverses TGF- β 1-Induced EMT in MCF-10A Non-Tumorigenic Breast Cells. <i>Cancers (Basel)</i> . 2023 Apr 15;15(8):2317. doi: 10.3390/cancers15082317. PMID: 37190245; PMCID: PMC10136889	5,2	2	Bizzarri M
2	Last name	Paradoxical E-cadherin increase in 5FU-resistant colon cancer is unaffected during mesenchymal-epithelial reversion induced by γ -secretase inhibition. Dinicola S, Pasqualato A, Proietti S, Masiello MG, Palombo A, Coluccia P, Canipari R, Catizone A, Ricci G, Harrath AH, Alwasel SH, Cucina A, Bizzarri M. <i>Life Sci</i> . 2016 ;145:174-183. doi: 10.1016/j.lfs.2015.12.048	2,94	9	Bizzarri M
3	First name	Bizzarri M, Brash DE, Briscoe J, Grieneisen VA, Stern CD, Levin M. A call for a better understanding of causation in cell biology. <i>Nat Rev Mol Cell Biol</i> . 2019. doi: 10.1038/s41580-019-0130-6	55,47	42	-
4	-	Feriani A, Bizzarri M, Tir M, Aldawood N, Alobaid H, Allagui MS, Dahmash W, Tlili N, Mnafigui K, Alwasel S, Harrath AH. High-fat diet-induced aggravation of cardiovascular impairment in permethrin-treated Wistar rats.	7,12	25	-

		Ecotoxicol Environ Saf. 2021 Jul 2;222:112461. doi: 10.1016/j.ecoenv.2021.112461. Epub ahead of print. PMID: 34224971.			
5	First name	Bizzarri M, Di Traglia M, Giuliani A, Vestri A, Fedeli V, Prestininzi A. New statistical RI index allow to better track the dynamics of COVID-19 outbreak in Italy. <i>Sci Rep.</i> 2020 Dec 22;10(1):22365. doi: 10.1038/s41598-020-79039-x. PMID: 33353964; PMCID: PMC7755893	4,96	7	Bizzarri M
6	Last name	Proietti S, Cucina A, Catizone A, Ricci G, Pensotti A, Bizzarri M. Zebrafish embryo extracts enhance 5-FU anti-cancer effects upon breast cancer cells. <i>Eur Rev Med Pharmacol Sci.</i> 2021 Apr;25(8):3235-3245. doi: 10.26355/eurrev_202104_25732. PMID: 33928609	3,8	5	Bizzarri M
7	Last name	Proietti S, Cucina A, Dobrowolny G, D'Anselmi F, Dinicola S, Masiello MG, Pasqualato A, Palombo A, Morini V, Reiter RJ, Bizzarri M. Melatonin down-regulates MDM2 gene expression and enhances p53 acetylation in MCF-7 cells. <i>J Pineal Res.</i> 2014 , 57(1):120-9	9,6	43	Bizzarri M
8	Last name	R. Verna, S. Proietti, A. Spiga, V. Unfer, M. Bizzarri. Nebulized myo-inositol increases mucus clearance in patients with Bronchiectasis: a retrospective study. <i>Eur Rev Med Pharmacol Sci</i> , 2023, 27 (14): 6876-6881. DOI: 10.26355/eurrev_202307_33159	3,7	1	Bizzarri M
9	-	Ranieri D, Avitabile D, Shiota M, Yokomizo A, Naito S, Bizzarri M, Torrisi MR. Nuclear redox imbalance affects circadian oscillation in HaCaT keratinocytes. <i>Int J Biochem Cell Biol.</i> 2015 , 65:113-24	3,9	27	-
10	Last name	Minini M, Senni A, He X, Proietti S, Liguoro D, Catizone A, Giuliani A, Mancini R, Fuso A, Cucina A, Cao Y, Bizzarri M. miR-125a-5p impairs the metastatic potential in breast cancer via IP6K1 targeting. <i>Cancer Lett.</i> 2021 Nov 1;520:48-56. doi: 10.1016/j.canlet.2021.07.001. Epub 2021 Jul 3. PMID: 34229060.	9,75	12	Bizzarri M
11	Last name	Monti N, Masiello MG, Proietti S, Catizone A, Ricci G, Harrath AH, Alwasel SH, Cucina A, Bizzarri M. Survival Pathways Are Differently Affected by Microgravity in Normal and Cancerous Breast Cells. <i>Int J Mol Sci.</i> 2021 Jan 16;22(2):862. doi: 10.3390/ijms22020862. PMID: 33467082; PMCID: PMC7829699	6,2	21	Bizzarri M
12	Last name	Agnese Po, Alessandro Giuliani, Maria Grazia Masiello, Alessandra Cucina, Angela Catizone, Giulia Ricci, Martina Chiacchiarini, Marco Tafani, Elisabetta Ferretti, and Mariano Bizzarri. Phenotypic transitions enacted by	3,4	28	Bizzarri M

		microgravity do not alter coherence in gene transcription profile, <i>Nature microgravity</i> , 2019 Nov 21;5:27. doi: 10.1038/s41526-019-0088-x. PMID: 31799378; PMCID: PMC6872.			
13	Last name	Proietti S, Cucina A, Pensotti A, Biava PM, Minini M, Monti N, Catizone A, Ricci G, Leonetti E, Harrath AH, Alwasel SH, Bizzarri M. Active Fraction from Embryo Fish Extracts Induces Reversion of the Malignant Invasive Phenotype in Breast Cancer through Down-regulation of TCTP and Modulation of E-cadherin/ β -catenin Pathway. <i>Int J Mol Sci</i> . 2019 Apr 30;20(9)	4,55	32	Bizzarri M
14	Last name	Bevilacqua A, Dragotto J, Giuliani A, Bizzarri M. Myo-inositol and D-chiro-inositol (40:1) reverse histological and functional features of polycystic ovary syndrome in a mouse model. <i>J Cell Physiol</i> . 2018 Oct 14. doi: 10.1002/jcp.27623	5,52	94	Bizzarri M
15	Last name	Proietti S, Catizone A, Masiello MG, Dinicola S, Fabrizi G, Minini M, Ricci G, Verna R, Reiter RJ, Cucina A, Bizzarri M. Increase in motility and invasiveness of MCF7 cancer cells induced by nicotine is abolished by melatonin through inhibition of ERK phosphorylation. <i>J Pineal Res</i> . 2018 Jan 16. doi: 10.1111/jpi.12467	15,22	38	Bizzarri M
16	Last name	Dinicola S, Fabrizi G, Masiello MG, Proietti S, Palombo A, Minini M, Harrath AH, Alwasel SH, Ricci G, Catizone A, Cucina A, Bizzarri M. Inositol induces mesenchymal-epithelial reversion in breast cancer cells through cytoskeleton rearrangement. <i>Exp Cell Res</i> . 2016 Jul 1;345(1):37-50	3,54	70	Bizzarri M

Part X – Plenary Invited Lectures and Keynotes in International Meetings

15-18 May, 1985	Budapest (Hungary). Invited by the European Society of Urology. International Congress of Urology. Symposium on Prostate cancer. Title: «Flutamide in the treatment of advanced prostate cancer».
3-4 April, 1987	Taranto (Italy), Ethics, science and law for citizens' health . Title: «why does a cancer patient die?»
14 December, 1991	Anno Europeo per la sicurezza e la salute sul lavoro – Taranto. Title: «Cancer incidence among ITALSIDER workers».
15-16 June, 2004	Chemistry of the Future, Rome. Plenary lecture. Title: «The journey of chemistry, from alchemy to science»
28 September, 2007	Alma Mater Bologna – Plenary lecture. Title: «Biomedicine and Biotechnologies for Space Missions»
27 March, 2010	Milano – International Congress on Biophysics. Plenary lecture in honor of the Nobel Laureate, Prof. Luc Montagnier. Title «Tumor cell phenotypes as attractors in the phase space described by fractal and dissipative function parameters»

17 October, 2012	Istituto Italiano di Cultura de Paris – Invited lecture. Title: «Human Space Flight: the ASI roadmap»
27 June, 2013	University Aldo Moro – Bari. Plenary lecture: «Metabolomics and shape changes in cells and tissues exposed to microgravity»
June 14-16, 2014	European Society of Thoracic Surgeons - 22 nd European Conference on General Thoracic Surgery - Copenhagen, Denmark – Plenary lecture: « How diagnosis and management of lung diseases can benefit from advanced space technologies»
13-16 June, 2016	Urbaniana University (Rome); IMCL international congress. Title: «How the environment influences human DNA»
13 October, 2018	Antalya (Turkey) - 5th EFLM-UEMS European Joint Congress - Inositol metabolites as biomarkers of peripheral complications in insulin resistant and diabetes patients
10 April, 2018	Faculty of Science, Charles University in Prague. Title: «Tumor reversion by manipulating the microenvironment». Departmental plenary lecture.
21 February, 2019	Perm (Russia), XXI Winter School on Continuous Media Mechanics. Title: «Physical forces and nonlinear cell dynamics»
14-15 November, 2022	Warsaw (Poland), International Congress on Future perspective in medicine (organized by the Geriatric Society of Poland). Title: «Medicine in the post-Covid era»
19-21 February, 2023	Torun Poland. Invited plenary lecture during the first «Nicola Copernicus» Academy meeting. Title: «perspectives of new biomedical technologies.
28 May, 2024	International Workshop (Novara) – Title: «tumor reversion»

Part XI – Organization of National and International Meetings

Year	Title
15 Dec., 1983	Tumor Markers in Oncology - Rome
12 Nov., 2002	OGM: Il tempo delle scelte - Rome
14-15 March, 2006	Space Biomedicine – ISSBB (Italian Society for Space Biomedicine and Biotechnology) - Rome
29-31 March, 2007	Conquests of Space Biomedicine – ISSBB (Italian Society for Space Biomedicine and Biotechnology) - Bari
28-30 March, 2009	A word without gravity - ISSBB (Italian Society for Space Biomedicine and Biotechnology) – St. Margherita Ligure
14 Oct., 2011	The driving force of science fiction in scientific research - Rome
25-27 Oct., 2017	Where are the Biological Sciences Going? Rome
26 Jan., 2018	Light on Melatonin - Rome

Part XII– Complete list of publications

2024

195) Fedeli V, Unfer V, Dinicola S, Laganà AS, Canipari R, Monti N, Querqui A, Galante E, Laurenzi G, Bizzarri M. Inositol Restores Appropriate Steroidogenesis in PCOS Ovaries Both In Vitro and In Vivo Experimental Mouse Models. *Cells*. 2024 Jul 9;13(14):1171. doi: 10.3390/cells13141171. PMID: 39056753; PMCID: PMC11275052. IF 6.0

194) Škarková A, Bizzarri M, Janoštiak R, Mašek J, Rosel D, Brábek J. Educate, not kill: treating cancer without triggering its defenses. *Trends Mol Med*. 2024 Apr 23:S1471-4914(24)00091-1. doi: 10.1016/j.molmed.2024.04.003. Epub ahead of print. PMID: 38658206. IF 12.8

193) Dinicola S, Unfer V, Soulage CO, Yap-Garcia MIM, Bevilacqua A, Benvenga S, Barbaro D, Wdowiak A, Nordio M, Dewailly D, Appetecchia M, Aragona C, Espinola MSB, Bizzarri M, Cavalli P, Colao A, D'Anna R, Vazquez-Levin MH, Hernández Marin I, Kamenov Z, Laganà AS, Monastra G, Montanino Oliva M, Cenik Özay A, Pintaudi B, Porcaro G, Pustotina O, Pkhaladze L, Prapas N, Roseff S, Salehpour S, Stringaro A, Tugushev M, Unfer V, Vucenic I, Facchinetti F. D-chiro-inositol in clinical practice: A perspective from The Experts Group on Inositol in Basic and Clinical Research (EGOI). *Gynecol Obstet Invest*. 2024 Feb 19. doi: 10.1159/000536081. Epub ahead of print. PMID: 38373412. IF 2

192) Pensotti A, Bizzarri M, Bertolaso M. The phenotypic reversion of cancer: Experimental evidences on cancer reversibility through epigenetic mechanisms (Review). *Oncol Rep*. 2024 Mar;51(3):48. doi: 10.3892/or.2024.8707. Epub 2024 Jan 26. PMID: 38275101. IF 3.9

191) Monti N, Querqui A, Lentini G, Tafani M, Bizzarri M. System Biology Approach in Investigating Epithelial-Mesenchymal Transition (EMT). *Methods Mol Biol*. 2024;2745:211-225. doi: 10.1007/978-1-0716-3577-3_13. PMID: 38060188.

190) Piombarolo A, Ialongo C, Bizzarri M, Angeloni A. Systems Biology and Inborn Error of Metabolism: Analytical Strategy in Investigating Different Biochemical/Genetic Parameters. *Methods Mol Biol*. 2024;2745:191-210. doi: 10.1007/978-1-0716-3577-3_12. PMID: 38060187.

2023

189) Tortolini, C.; Gigli, V.; Rizzo, F.; Lenzi, A.; Bizzarri, M.; Angeloni, A.; Antiochia, R. Stereoselective Voltammetric Biosensor for Myo-Inositol and D-Chiro-Inositol Recognition. *Sensors* 2023, 23, 9211. <https://doi.org/10.3390/s23229211> IF 3.84

188) M. Bizzarri, P. Gaudenzi, A. Angeloni. The Biomedical challenge associated with the Artemis space program. *Acta Astronautica*, 212 (2023) 14–28. doi.org/10.1016/j.actaastro.2023.07.021 IF 2.95

187) R. Verna, S. Proietti, A. Spiga, V. Unfer, M. Bizzarri. Nebulized myo-inositol increases mucus clearance in patients with Bronchiectasis: a retrospective study. *Eur Rev Med Pharmacol Sci*, 2023, 27 (14): 6876-6881. DOI: 10.26355/eurev_202307_33159 . IF 3.78

186) Gesualdi, L.; Berardini, M.; Scicchitano, B.M.; Castaldo, C.; Bizzarri, M.; Filippini, A.; Riccioli, A.; Schiraldi, C.; Ferranti, F.; Liguoro, D.; et al. ERK Signaling Pathway Is Constitutively Active in NT2D1 Non-Seminoma Cells and Its Inhibition Impairs Basal and HGF-Activated Cell Proliferation. *Biomedicines* 2023, 11, 1894. <https://doi.org/10.3390/biomedicines11071894>. IF 4.74

185) Tsuchiya, M.; Brazhnik, P.; Bizzarri, M.; Giuliani, A. Synchronization between Attractors: Genomic Mechanism of Cell-Fate Change. *Int. J. Mol. Sci.* 2023, 24, 11603. <https://doi.org/10.3390/ijms241411603> IF 5.6

184) Miglietta S, Cristiano L, Espinola MSB, Masiello MG, Micara G, Battaglione E, Linari A, Palmerini MG, Familiari G, Aragona C, Bizzarri M, Macchiarelli G, Nottola SA. Effects of Simulated Microgravity In Vitro on Human Metaphase II Oocytes: An Electron Microscopy-Based Study. *Cells*. 2023 May 9;12(10):1346. doi: 10.3390/cells12101346. PMID: 37408181; PMCID: PMC10216377. IF 6.0

183) Unfer V, Russo M, Aragona C, Bilotta G, Montanino Oliva M, Bizzarri M. Treatment with Myo-Inositol Does Not Improve the Clinical Features in All PCOS Phenotypes. *Biomedicines*. 2023 Jun 19;11(6):1759. doi: 10.3390/biomedicines11061759. PMID: 37371854; PMCID: PMC10296526. IF 4.74

182) Chiantera, V.; Laganà, A.S.; Basciani, S.; Nordio, M.; Bizzarri, M. A Critical Perspective on the Supplementation of *Akkermansia muciniphila*: Benefits and Harms. *Life* 2023, 13, 1247. <https://doi.org/10.3390/life13061247> IF 3.2

181) Monti N, Dinicola S, Querqui A, Fabrizi G, Fedeli V, Gesualdi L, Catizone A, Unfer V, Bizzarri M. Myo-Inositol Reverses TGF- β 1-Induced EMT in MCF-10A Non-Tumorigenic Breast Cells. *Cancers (Basel)*. 2023 Apr 15;15(8):2317. doi: 10.3390/cancers15082317. PMID: 37190245; PMCID: PMC10136889. IF 6.57

180) Pensotti A, Bertolaso M, Bizzarri M. Is Cancer Reversible? Rethinking Carcinogenesis Models-A New Epistemological Tool. *Biomolecules*. 2023 Apr 24;13(5):733. doi: 10.3390/biom13050733. PMID: 37238604; PMCID: PMC10216038. IF 6.06

179) Donadon M, Palmisano A, Bizzarri M, Ceriani R, Veneroni L, Donati G, Tassinari D, Viola MG, Tamburini E, Torzilli G. Impact of Oocyte Extract Supplement on Quality of Life after Hepatectomy for Liver Tumours: A Prospective, Multicentre, Double-Blind Randomized Clinical Trial. *Cancers (Basel)*. 2023 May 18;15(10):2809. doi: 10.3390/cancers15102809. PMID: 37345146. IF 6.57

178) Bizzarri M, Monti N, Piombo A, Angeloni A, Verna R. Myo-Inositol and D-Chiro-Inositol as Modulators of Ovary Steroidogenesis: A Narrative Review. *Nutrients*. 2023 Apr 13;15(8):1875. doi: 10.3390/nu15081875. PMID: 37111094; PMCID: PMC10145676. IF 6.208

177) Fedeli V, Catizone A, Querqui A, Unfer V, Bizzarri M. The Role of Inositols in the Hyperandrogenic Phenotypes of PCOS: A Re-Reading of Lerner's Results. *Int J Mol Sci*. 2023 Mar 27;24(7):6296. doi: 10.3390/ijms24076296. PMID: 37047265; PMCID: PMC10093919. IF 6.70

176) Aventaggiato M, Barreca F, Vitiello L, Vespa S, Valente S, Rotili D, Mai A, Lotti LV, Sansone L, Russo MA, Bizzarri M, Ferretti E, Tafani M. Role of SIRT3 in Microgravity Response: A New Player in Muscle Tissue Recovery. *Cells*. 2023 Feb 22;12(5):691. doi: 10.3390/cells12050691. PMID: 36899828; PMCID: PMC10000945. IF 7.66

175) Dumontet S, Giuliani A, Falco GD, Fedeli V, Bizzarri M (2023) Italian Mortality Time Series Underline Hidden Dynamics that Reveal Unexpected Links between COVID-19 Epidemic and North-South Divide. *J Infect Dis Ther* 11: 523. DOI: 10.4172/2332-0877.1000523 IF 2.81

2022

174) Bizzarri M, Fedeli V, Piombo A, Angeloni A. Space Biomedicine: A Unique Opportunity to Rethink the Relationships between Physics and Biology. *Biomedicine*. 2022 Oct 19;10(10):2633. doi: 10.3390/biomedicine10102633. PMID: 36289894. IF 5.612

173) Jalouli M, Mofti A, Elnakady YA, Nahdi S, Feriani A, Alrezaki A, Sebei K, Bizzarri M, Alwasel S, Harrath AH. Allethrin Promotes Apoptosis and Autophagy Associated with the Oxidative Stress-Related PI3K/AKT/mTOR Signaling Pathway in Developing Rat Ovaries. *Int J Mol Sci*. 2022 Jun 7;23(12):6397. doi: 10.3390/ijms23126397. PMID: 35742842; PMCID: PMC9224321. IF 6,208

172) Cardinale V, Lepore E, Basciani S, Artale S, Nordio M, Bizzarri M, Unfer V. Positive Effects of α -Lactalbumin in the Management of Symptoms of Polycystic Ovary Syndrome. *Nutrients*. 2022 Aug 6;14(15):3220. doi: 10.3390/nu14153220. PMID: 35956395; PMCID: PMC9370664. IF 5.719

171) De Bels D, Tillmans F, Corazza F, Bizzarri M, Germonpre P, Radermacher P, Orman KG, Balestra C. Hyperoxia Alters Ultrastructure and Induces Apoptosis in Leukemia Cell Lines. *Biomolecules*. 2020 Feb 12;10(2):282. doi: 10.3390/biom10020282. PMID: 32059539; PMCID: PMC7072400. IF 4,57

170) Bizzarri M, Giuliani A. Soft Statistical Mechanics for Biology. *Methods Mol Biol*. 2022;2449:263-280. doi: 10.1007/978-1-0716-2095-3_11. PMID: 35507267. IF 1,25

169) Laganà AS, Forte G, Bizzarri M, Kamenov Z, Bianco B, Kaya C, Gitas G, Alkatout I, Terzic M, Unfer V. Inositols in the ovaries: activities and potential therapeutic applications. *Expert Opin Drug Metab Toxicol*. 2022 Apr 26. doi: 10.1080/17425255.2022.2071259. Epub ahead of print. PMID: 35472446. IF 3.507

168) Bizzarri M., Pontecorvi P. Microenvironment promotes cytoskeleton remodeling and adaptive phenotypic transition. *BIOCELL*, Vol.46, No.6, pp. 1357-1362, 2022, DOI:10.32604/biocell.2022.018471. IF 1,25

167) Ahmed Bakry, MARTINELLI, Andrea, BIZZARRI, Mariano, CUCINA, Alessandra, D'ILARIO, LUCIO, FRANCOLINI, IOLANDA, PIOZZI, Antonella, PROIETTI, SARA (2012). A new approach for the preparation of hydrophilic poly(L-lactide) porous scaffold for tissue engineering by using lamellar single crystals. *POLYMER INTERNATIONAL*, vol. 61, p. 1177-1185, ISSN: 0959-8103, doi: 10.1002/pi.4197 IF 2.72

166) Laganà AS, Monti N, Fedeli V, Gullo G, Bizzarri M. Does Alpha-lipoic acid improve effects on polycystic ovary syndrome? *Eur Rev Med Pharmacol Sci*. 2022 Feb;26(4):1241-1247. doi: 10.26355/eurrev_202202_28116. PMID: 35253180. IF 5.50

165) Laganà, Antonio Simone, Veronesi, Giovanni, Ghezzi, Fabio, Ferrario, Marco Mario, Cromi, Antonella, Bizzarri, Mariano, Garzon, Simone and Cosentino, Marco. "Evaluation of menstrual irregularities after COVID-19 vaccination: Results of the MECOVAC survey" *Open Medicine*, vol. 17, no. 1, 2022, pp. 475-484. <https://doi.org/10.1515/med-2022-0452> . IF 2.19

164) Fedeli V, Cucina A, Dinicola S, Fabrizi G, Catizone A, Gesualdi L, Ceccarelli S, Harrath AH, Alwasel SH, Ricci G, Pedata P, Bizzarri M, Monti N. Microgravity Modifies the Phenotype of Fibroblast and Promotes Remodeling of the Fibroblast-Keratinocyte Interaction in a 3D Co-Culture Model. *Int J Mol Sci*. 2022 Feb 16;23(4):2163. doi: 10.3390/ijms23042163. PMID: 35216279. IF 5.60 IF

2021

163) Dinicola S, Unfer V, Facchinetti F, Soulage CO, Greene ND, Bizzarri M, Laganà AS, Chan SY, Bevilacqua A, Pkhaladze L, Benvenga S, Stringaro A, Barbaro D, Appetecchia M, Aragona C, Bezerra Espinola MS, Cantelmi T, Cavalli P, Chiu TT, Copp AJ, D'Anna R, Dewailly D, Di Lorenzo C, Diamanti-Kandarakis E, Hernández Marín I, Hod M, Kamenov Z, Kandaraki E, Monastra G, Montanino Oliva M, Nestler JE, Nordio M, Ozay AC, Papalou O, Porcaro G, Prapas N, Roseff S, Vazquez-Levin M, Vucenik I, Wdowiak A. Inositols: From Established Knowledge to Novel Approaches. *Int J Mol Sci*. 2021 Sep 30;22(19):10575. doi: 10.3390/ijms221910575. PMID: 34638926; PMCID: PMC8508595. IF 5.92

162) Bizzarri M, Fedeli V, Monti N, Cucina A, Jalouli M, Alwasel SH, Harrath AH. Personalization of medical treatments in oncology: time for rethinking the disease concept to improve individual outcomes. *EPMA J*. 2021 Oct 7:1-14. doi: 10.1007/s13167-021-00254-1. Epub ahead of print. PMID: 34642594; PMCID: PMC8495186. IF 8,83

161) Verna R, Alallon W, Murakami M, Hayward CPM, Harrath AH, Alwasel SH, Sumita NM, Alatas O, Fedeli V, Sharma P, Fuso A, Capuano DM, Capalbo M, Angeloni A, Bizzarri M. Analytical Performance of COVID-19 Detection Methods (RT-PCR): Scientific and Societal Concerns. *Life (Basel)*. 2021 Jul 6;11(7):660. doi: 10.3390/life11070660. PMID: 34357032; PMCID: PMC8305061. IF 3,82

160) Feriani A, Bizzarri M, Tir M, Aldawood N, Alobaid H, Allagui MS, Dahmash W, Tlili N, Mnafigui K, Alwasel S, Harrath AH. High-fat diet-induced aggravation of cardiovascular impairment in permethrin-treated Wistar rats. *Ecotoxicol Environ Saf*. 2021 Jul 2;222:112461. doi: 10.1016/j.ecoenv.2021.112461. Epub ahead of print. PMID: 34224971. IF 7,12

159) Minini M, Senni A, He X, Proietti S, Liguoro D, Catizone A, Giuliani A, Mancini R, Fuso A, Cucina A, Cao Y, Bizzarri M. miR-125a-5p impairs the metastatic potential in breast cancer via IP6K1 targeting. *Cancer Lett*. 2021 Nov 1;520:48-56. doi: 10.1016/j.canlet.2021.07.001. Epub 2021 Jul 3. PMID: 34229060. IF 9,75

158) Bizzarri M, Logoteta P, Monastra G, Laganà AS. An innovative approach to polycystic ovary syndrome. *J Obstet Gynaecol*. 2021 Jun 25:1-11. doi: 10.1080/01443615.2021.1920006. Epub ahead of print. PMID: 34169781. IF 1.4

157) Bizzarri M, Pontecorvi P. Critical transition across the Waddington landscape as an interpretative model: Comment on "Dynamic and thermodynamic models of adaptation" by A.N. Gorban et al. *Phys Life Rev.* 2021 Jun 6:S1571-0645(21)00039-7. doi: 10.1016/j.plrev.2021.05.010. Epub ahead of print. PMID: 34116954. IF 14,789

156) Proietti S, Cucina A, Catizone A, Ricci G, Pensotti A, Bizzarri M. Zebrafish embryo extracts enhance 5-FU anti-cancer effects upon breast cancer cells. *Eur Rev Med Pharmacol Sci.* 2021 Apr;25(8):3235-3245. doi: 10.26355/eurev_202104_25732. PMID: 33928609. IF 3,78

155) Monastra G, Vucenik I, Harrath AH, Alwasel SH, Kamenov ZA, Laganà AS, Monti N, Fedeli V, Bizzarri M. PCOS and Inositols: Controversial Results and Necessary Clarifications. Basic Differences Between D-Chiro and Myo-Inositol. *Front Endocrinol (Lausanne).* 2021 Apr 6;12:660381. doi: 10.3389/fendo.2021.660381. PMID: 33889133; PMCID: PMC8056130. IF 4,85

154) Gambioli R, Forte G, Aragona C, Bevilacqua A, Bizzarri M, Unfer V. The use of D-chiro-Inositol in clinical practice. *Eur Rev Med Pharmacol Sci.* 2021 Jan;25(1):438-446. doi: 10.26355/eurev_202101_24412. PMID: 33506934. IF 3,024

153) Bezerra Espinola MS, Bertelli M, Bizzarri M, Unfer V, Laganà AS, Visconti B, Aragona C. Inositol and vitamin D may naturally protect human reproduction and women undergoing assisted reproduction from Covid-19 risk. *J Reprod Immunol.* 2021 Jan 8;144:103271. doi: 10.1016/j.jri.2021.103271. Epub ahead of print. PMID: 33493945; PMCID: PMC7833496. IF 2,58

152) Monti N, Masiello MG, Proietti S, Catizone A, Ricci G, Harrath AH, Alwasel SH, Cucina A, Bizzarri M. Survival Pathways Are Differently Affected by Microgravity in Normal and Cancerous Breast Cells. *Int J Mol Sci.* 2021 Jan 16;22(2):862. doi: 10.3390/ijms22020862. PMID: 33467082; PMCID: PMC7829699. IF 4,55

2020

151) Facchinetti F, Cavalli P, Copp AJ, D'Anna R, Kandaraki E, Greene NDE, Unfer V; Experts Group on Inositol in Basic and Clinical Research. An update on the use of inositols in preventing gestational diabetes mellitus (GDM) and neural tube defects (NTDs). *Expert Opin Drug Metab Toxicol.* 2020 Dec;16(12):1187-1198. doi: 10.1080/17425255.2020.1828344. Epub 2020 Nov 10. PMID: 32966143. IF 3,59

150) Minini M, Senni A, Unfer V, Bizzarri M. The Key Role of IP6K: A Novel Target for Anticancer Treatments? *Molecules.* 2020 Sep 25;25(19):4401. doi: 10.3390/molecules25194401. PMID: 32992691; PMCID: PMC7583815. IF 3,010

149) Laganà AS, Unfer V, Garzon S, Bizzarri M. Role of inositol to improve surfactant functions and reduce IL-6 levels: A potential adjuvant strategy for SARS-CoV-2 pneumonia? *Med Hypotheses.* 2020 Nov;144:110262. doi: 10.1016/j.mehy.2020.110262. Epub 2020 Sep 9. PMID: 33254564; PMCID: PMC7480225. IF 1,37

148) Bizzarri M, Di Traglia M, Giuliani A, Vestri A, Fedeli V, Prestininzi A. New statistical RI index allow to better track the dynamics of COVID-19 outbreak in Italy. *Sci Rep.* 2020 Dec 22;10(1):22365. doi: 10.1038/s41598-020-79039-x. PMID: 33353964; PMCID: PMC7755893. IF 4,12

147) Gesualdi L, Leonetti E, Cucina A, Scicchitano BM, Sorrentino S, Tarsitano MG, Isidori A, Bizzarri M, Filippini A, Riccioli A, Cammarota M, Gigantino V, Ricci G, Catizone A. The PI3K/AKT Pathway Is Activated by HGF in NT2D1 Non-Seminoma Cells and Has a Role in the Modulation of Their Malignant Behavior. *Int J Mol Sci.* 2020 Nov 17;21(22):E8669. doi: 10.3390/ijms21228669. PMID: 33212946. IF 4,65

146) Proietti S, Cucina A, Pensotti A, Fuso A, Marchese C, Nicolini A, Bizzarri M. Tumor reversion and embryo morphogenetic factors. *Semin Cancer Biol.* 2022 Feb;79:83-90. doi: 10.1016/j.semcancer.2020.09.005. Epub 2020 Sep 10. PMID: 32920125. IF 10,0

145) Orrù B, Szekeres-Bartho J, Bizzarri M, Spiga AM, Unfer V. Inhibitory effects of Vitamin D on inflammation and IL-6 release. A further support for COVID-19 management? *Eur Rev Med Pharmacol Sci.* 2020 Aug;24(15):8187-8193. doi: 10.26355/eurev_202008_22507. PMID: 32767348. IF 3,024

- 144) Unfer V, Dinicola S, Laganà AS, Bizzarri M. Altered Ovarian Inositol Ratios May Account for Pathological Steroidogenesis in PCOS. *Int J Mol Sci.* 2020 Sep 28;21(19):7157. doi: 10.3390/ijms21197157. PMID: 32998310; PMCID: PMC7582282. IF 4.65
- 143) Maroufi NF, Ashouri N, Mortezaia Z, Ashoori Z, Vahedian V, Amirzadeh-Iranaq MT, Fattahi A, Kazemzadeh H, Bizzarri M, Akbarzadeh M, Nejabati HR, Faridvand Y, Rashidi MR, Nouri M. The potential therapeutic effects of melatonin on breast cancer: An invasion and metastasis inhibitor. *Pathol Res Pract.* 2020 Oct;216(10):153226. doi: 10.1016/j.prp.2020.153226. Epub 2020 Sep 19. PMID: 32987338. IF 1,8
- 142) M. Bizzarri, O. Naimark, J. Nieto-Villar, V. Fedeli and A. Giuliani. Complexity in Biological Organization: Deconstruction (and Subsequent Restating) of Key Concepts. *Entropy* 2020, 22(8), 885; <https://doi.org/10.3390/e22080885> IF 2,7
- 141) M. Aventaggiato, F. Barreca, E. Vernucci, M. Bizzarri, E. Ferretti, M. A. Russo and M. Tafani. Putative Receptors for Gravity Sensing in Mammalian Cells: The Effects of Microgravity. *Appl. Sci.* 2020, 10(6), 2028; <https://doi.org/10.3390/app10062028>. IF 1,8
- 140) Martino A, Giuliani A, Todde V, Bizzarri M, Rizzi A. Metabolic networks classification and knowledge discovery by information granulation. *Comput Biol Chem.* 2020, 84:107187. doi: 10.1016/j.combiolchem.2019.107187. IF 1.69
- 139) Bizzarri M, Giuliani A, Cucina A, Minini M. Redifferentiation therapeutic strategies in cancer. *Drug Discov Today.* 2020, 25(4):731-738. doi: 10.1016/j.drudis.2020.01.021 IF 6.86
- 138) Bizzarri M, Giuliani A, Minini M, Monti N, Cucina A. Constraints Shape Cell Function and Morphology by Canalizing the Developmental Path along the Waddington's Landscape. *Bioessays.* 2020, 42(4):e1900108. doi: 10.1002/bies.201900108 IF 4.1
- 137) Morabito C, Guarnieri S, Cucina A, Bizzarri M, Marigiò MA. Antioxidant Strategy to Prevent Simulated Microgravity-Induced Effects on Bone Osteoblasts. *Int J Mol Sci.* 2020, 21(10):E3638. doi: 10.3390/ijms21103638 IF 4.33
- 136) Facchinetti F, Appetecchia M, Aragona C, Bevilacqua A, Bezerra Espinola MS, Bizzarri M, D'Anna R, Dewailly D, Diamanti-Kandaraki E, Hernández Marín I, Kamenov ZA, Kandaraki E, Laganà AS, Monastera G, Montanino Oliva M, Nestler JE, Orio F, Ozay AC, Papalou O, Pkhaladze L, Porcaro G, Prapas N, Soulage CO, Stringaro A, Wdowiak A, Unfer V. Experts' opinion on inositols in treating polycystic ovary syndrome and non-insulin dependent diabetes mellitus: a further help for human reproduction and beyond. *Expert Opin Drug Metab Toxicol.* 2020, 16(3):255-274. doi: 10.1080/17425255.2020.1737675. IF 3.58
- 135) Bizzarri M, Giuliani A, Monti N, Verna R, Pensotti A, Cucina A. Rediscovery of natural compounds acting via multitarget recognition and noncanonical pharmacodynamical actions. *Drug Discov Today.* 2020, S1359-6446(20)30080-5. doi: 10.1016/j.drudis.2020.02.010. IF 6.86
- 134) Bizzarri M, Laganà AS, Aragona D, Unfer V. Inositol and pulmonary function. Could myo-inositol treatment downregulate inflammation and cytokine release syndrome in SARS-CoV-2? *Eur Rev Med Pharmacol Sci.* 2020, 24(6):3426-3432. doi: 10.26355/eurrev_202003_20715. IF 2.72
- 133) Bizzarri M. "Constraining" the probability toward a specified attractor: Comment on: Morphogenesis as Bayesian inference: A variational approach to pattern formation and control in complex biological systems. *Phys Life Rev.* 2020, S1571-0645(20)30010-5. doi: 10.1016/j.plrev.2020.04.004. IF 12.67
- 132) Facchinetti F, Espinola MSB, Dewailly D, Ozay AC, Prapas N, Bizzarri M., Vazquez-Levin M, Wdowiak A, Unfer V. Breakthroughs in the Use of Inositols for Assisted Reproductive Treatment (ART). Expert Group on Inositols in Preclinical and Clinical Research. *Trends Endocrinol Metab.* 2020, S1043-2760(20)30080-1. doi: 10.1016/j.tem.2020.04.003 IF 8.5

131) J.P. Pomuceno-Orduñez, E. Silva, R.R. Martin, I. Durán, M. Bizzarri, G. Cocho, R. Mansilla, J.M. Nieto-Villar. Phase transitions in tumor growth VII: The effect of periodic glucose pulses and privations in a cancer model *Integr Cancer Sci Therap*, 2019, 6: 1-7, IF 0,14

130) Agnese Po, Alessandro Giuliani, Maria Grazia Masiello, Alessandra Cucina, Angela Catizone, Giulia Ricci, Martina Chiacchiarini, Marco Tafani, Elisabetta Ferretti, and Mariano Bizzarri. Phenotypic transitions enacted by microgravity do not alter coherence in gene transcription profile, *Nature microgravity*, 2019 Nov 21;5:27. doi: 10.1038/s41526-019-0088-x. PMID: 31799378; PMCID: PMC6872. IF 3.111

129) Bizzarri M, Giuliani A, Pensotti A, Ratti E, Bertolaso M. Co-emergence and Collapse: The Mesoscopic Approach for Conceptualizing and Investigating the Functional Integration of Organisms. *Front Physiol*. 2019 Jul 26;10:924. doi: 10.3389/fphys.2019.00924. IF 3.394

128) Proietti S, Cucina A, Pensotti A, Biava PM, Minini M, Monti N, Catizone A, Ricci G, Leonetti E, Harrath AH, Alwasel SH, Bizzarri M. Active Fraction from Embryo Fish Extracts Induces Reversion of the Malignant Invasive Phenotype in Breast Cancer through Down-regulation of TCTP and Modulation of E-cadherin/ β -catenin Pathway. *Int J Mol Sci*. 2019 Apr 30;20(9) IF 4.183

127) Morabito C, Lanuti P, Caprara GA, Marchisio M, Bizzarri M, Guarnieri S, Mariggì MA. Physiological Responses of Jurkat Lymphocytes to Simulated Microgravity Conditions. *Int J Mol Sci*. 2019, 20(8). pii: E1892. doi: 10.3390/ijms20081892 IF 4.183

126) Costantini D, Overi D, Casadei L, Cardinale V, Nevi L, Carpino G, Di Matteo S, Safarikia S, Valerio M, Melandro F, Bizzarri M, Manetti C, Berloco PB, Gaudio E, Alvaro D. Simulated microgravity promotes the formation of tridimensional cultures and stimulates pluripotency and a glycolytic metabolism in human hepatic and biliary tree stem/progenitor cells. *Sci Rep*. 2019, 9(1):5559. doi: 10.1038/s41598-019-41908-5. IF 4.52

125) Bizzarri M, Brash DE, Briscoe J, Grieneisen VA, Stern CD, Levin M. A call for a better understanding of causation in cell biology. *Nat Rev Mol Cell Biol*. 2019. doi: 10.1038/s41580-019-0130-6 IF 55,35

124) Leonetti E, Gesualdi L, Scheri KC, Dinicola S, Fattore L, Masiello MG, Cucina A, Mancini R, Bizzarri M, Ricci G, Catizone A. c-Src Recruitment is Involved in c-MET-Mediated Malignant Behaviour of NT2D1 Non-Seminoma Cells. *Int J Mol Sci*. 2019 Jan 14;20(2). pii: E320. doi: 10.3390/ijms20020320 IF 4.183

2018

123) Bizzarri, M, 2018, "Sorcerer's apprentices at work", *Organisms. Journal of Biological Sciences*, vol. 2, no. 2, pp.51-58.

122) A. Guerra, D.J. Rodriguez, S. Montero, J.A. Betancourt-Mar, R.R. Martin, E. Silva, M. Bizzarri, G. Cocho, R. Mansilla, J.M. Nieto-Villar. Phase transitions in tumor growth VI: Epithelial-Mesenchymal transition *Physica A* 499 (2018) 208–215 IF 2,50

119) Bizzarri, M, 2018, "How relevant are genes for understanding biological process", *Organisms. Journal of Biological Sciences*, vol. 2, no. 2, pp. 3- 4.

121) Bizzarri, M, 2018, "Lessons from the past. Hildegard of Bingen", *Organisms. Journal of Biological Sciences*, vol. 2, no. 1, pp. 113-116.

120) Bizzarri, M, 2018, "There is something rotten in the state of the Pharma Industry", *Organisms. Journal of Biological Sciences*, vol. 2, no. 1, pp. 11-13

119) Bizzarri, M, 2018, "The courage (necessary) to go further", *Organisms. Journal of Biological Sciences*, vol. 2, no. 1, pp. 9-10

- 118) Bevilacqua A, Bizzarri M. Inositols in Insulin Signaling and Glucose Metabolism. *Int J Endocrinol*. 2018 Nov 25;2018:1968450. doi: 10.1155/2018/1968450 IF 2,28
- 117) Scheri KC, Leonetti E, Laino L, Gigantino V, Gesualdi L, Grammatico P, Bizzarri M, Franco R, Oosterhuis JW, Stoop H, Looijenga LHJ, Ricci G, Catizone A.. c-MET receptor as potential biomarker and target molecule for malignant testicular germ cell tumors. *Oncotarget*. 2018, 9(61):31842-31860 IF 5.16
- 116) Bevilacqua A, Dragotto J, Giuliani A, Bizzarri M. Myo-inositol and D-chiro-inositol (40:1) reverse histological and functional features of polycystic ovary syndrome in a mouse model. *J Cell Physiol*. 2018 Oct 14. doi: 10.1002/jcp.27623 IF 4.52
- 115) Dinicola S, Fuso A, Cucina A, Santiago-Reyes M, Verna R, Unfer V, Monastra G, Bizzarri M. Eur. Natural products - alpha-lipoic acid and acetyl-L-carnitine - in the treatment of chemotherapy-induced peripheral neuropathy. *Eur. Rev Med Pharmacol Sci*. 2018, 22(14):4739-475 IF 2.721
- 114) Proietti S, Catizone A, Masiello MG, Dinicola S, Fabrizi G, Minini M, Ricci G, Verna R, Reiter RJ, Cucina A, Bizzarri M. Increase in motility and invasiveness of MCF7 cancer cells induced by nicotine is abolished by melatonin through inhibition of ERK phosphorylation. *J Pineal Res*. 2018 Jan 16. doi: 10.1111/jpi.12467 IF 15.221
- 113) Masiello MG, Verna R, Cucina A, Bizzarri M. Physical constraints in cell fate specification. A case in point: Microgravity and phenotypes differentiation. *Prog Biophys Mol Biol*. 2018 Jan 4. pii: S0079-6107(17)30313-9. doi: 10.1016/j.pbiomolbio.2018.01.001 IF 2.703
- 112) Bizzarri M, Masiello MG, Giuliani A, Cucina A. Gravity Constraints Drive Biological Systems Toward Specific Organization Patterns: Commitment of cell specification is constrained by physical cues. *Bioessays*. 2018 Jan;40(1). doi: 10.1002/bies.201700138. Epub 2017 Nov 14 IF 4.396
- 2017
- 111) Bizzarri, M, Masiello, MG, Cucina, A, & Pensotti, A, 2017, "Gravity constraint in cell phenotypic determination", *Organisms. Journal of Biological Sciences*, vol. 1, no. 2, pp.61 – 68 IF 3.111
- 110) Bizzarri, M, 2017, It's a long way to Tipperary, *Organisms. Journal of Biological Sciences*, vol. 1, no. 1, p. 5.
- 109) Bizzarri, M, Masiello, MG, & Cucina, A, Guzzi, R, 2017, "Journey to Mars: A Biomedical Challenge. Perspective on future human space flight", *Organisms. Journal of Biological Sciences*, vol. 1, no. 2, pp. 15-26
- 108) Bizzarri, M, 2017, "Are GM crops really safe? Europe still needs to be convinced. Notwithstanding political inconsistencies, scientific evidence urges to reconsider glyphosate safety", *Organisms. Journal of Biological Sciences*, vol. 1, no. 2, pp. 9- 10.
- 107) Bizzarri M, 2017, Do new anticancer drugs really work? A serious concern, *Organisms. Journal of Biological Sciences*, vol. 1, no. 1, pp. 9 - 10
- 106) Kzhyshkowska J, Bizzarri M, Apte R, Cherdynitseva N. Editorial: Targeting of Cancer Cells and Tumor Microenvironment: Perspectives for Personalized Therapy. *Curr Pharm Des*. 2017;23(32):4703-4704. doi: 10.2174/138161282332171221165319. IF 2,41
- 105) Montanari G., Zaami S., di Luca A., di Luca NM, Bizzarri M., Marinelli E. The doctor-patient relationship in telemedicine and mobile health *Senses and Sciences* 2017, (1), 331-337
- 104) Dinicola S., Santiago-Reyes M., Canipari R., Cucina A., Bizzarri M., Fuso A. Alpha-lipoic acid represses IL-1B and IL-6 through DNA methylation in ovarian cells. *Pharma Nutrition* 2017, 5 (3), 77-83 IF 1,56

- 103) Verma G, Luciani ML, Palombo A, Metaxa L, Panzironi G, Pediconi F, Giuliani A, Bizzarri M, Todde V. Microcalcification morphological descriptors and parenchyma fractal dimension hierarchically interact in breast cancer: A diagnostic perspective. *Comput Biol Med.* 2017 Dec 11;93:1-6. doi: 10.1016/j.combiomed.2017.12.004 IF 2,286
- 102) Dinicola S, Masiello MG, Proietti S, Coluccia P, Fabrizi G, Catizone A, Ricci G, De Toma G, Bizzarri M, Cucina A. Nicotine increases colon cancer cell migration and invasion through epithelial to mesenchymal transition (EMT): COX-2 involvement. *J Cell Physiol.* 2017 Dec 7. doi: 10.1002/jcp.26323. IF 4.522
- 101) Dinicola S, Minini M, Unfer V, Verna R, Cucina A, Bizzarri M. Nutritional and Acquired Deficiencies in Inositol Bioavailability. Correlations with Metabolic Disorders. *Int J Mol Sci.* 2017 Oct 20;18(10). pii: E2187. doi: 10.3390/ijms18102187. IF 3.687
- 100) Dinicola S, Proietti S, Cucina A, Bizzarri M, Fuso A. Alpha-Lipoic Acid Downregulates IL-1 β and IL-6 by DNA Hypermethylation in SK-N-BE Neuroblastoma Cells. *Antioxidants (Basel).* 2017 Sep 26;6(4). pii: E74. doi: 10.3390/antiox6040074. IF 6
- 99) Bizzarri M, Dinicola S, Cucina A. Modulation of both Insulin Resistance and Cancer Growth by Inositol. *Curr Pharm Des.* 2017 Aug 30. doi: 10.2174/1381612823666170830123634 IF 2.757
- 98) Proietti S, Cucina A, Minini M, Bizzarri M. Melatonin, mitochondria, and the cancer cell. *Cell Mol Life Sci.* 2017 Nov;74(21):4015-4025. IF 6.721
- 97) Bizzarri M, Cucina A, Proietti S. Tumor reversion: mesenchymal-epithelial transition as a critical step in managing the tumor-microenvironment cross talk. *Curr Pharm Des.* 2017 IF 2.757
- 96) Martin RR, Montero S., Silva E, Bizzarri M, Cocho G, Mansilla R, Villar JM. Phase transitions in tumor growth: V what can be expected from cancer glycolytic oscillations? *Physica A* 486 (2017) 762–771 IF 2.132
- 95) Ranieri D, Proietti S, Dinicola S, Masiello MG, Rosato B, Ricci G, Cucina A, Catizone A, Bizzarri M, Torrisi MR. Simulated microgravity triggers epithelial mesenchymal transition in human keratinocytes. *Sci Rep.* 2017 Apr 3;7(1):538. IF 4.122
- 94) Monastra G, Unfer V, Harrath AH, Bizzarri M. Combining treatment with myo-inositol and D-chiro-inositol (40:1) is effective in restoring ovary function and metabolic balance in PCOS patients. *Gynecol Endocrinol.* 2017, 33(1):1-9 IF 1.453
- 93) S. Proietti, V. Pasta, A. Cucina, C. Aragona, E. Palombi, I. Vucenik, M. Bizzarri. Inositol hexaphosphate (InsP6) as an effective topical treatment for patients receiving adjuvant chemotherapy after breast surgery. *Eur Rev Med Pharmacol Sci,* 2017 IF 2.387

2016

- 92) Bizzarri M, Dinicola S, Bevilacqua A, Cucina A. Broad Spectrum Anticancer Activity of Myo-Inositol and Inositol Hexakisphosphate. *Int J Endocrinol.* 2016. IF 2.510
- 91) Kuşcu N, Bizzarri M, Bevilacqua A. Myo-Inositol Safety in Pregnancy: From Preimplantation Development to Newborn Animals. *Int J Endocrinol.* 2016 IF 2.510
- 90) Bizzarri M., Fuso A, Dinicola S, Cucina A, Bevilacqua A. Pharmacodynamics and pharmacokinetics of inositol(s) in health and disease. *Expert Opin Drug Metab Toxicol.* 2016 Jul 14:1-16 IF 3.027
- 89) Bizzarri M. Warning about supplemental of Vitamin D in women looking for pregnancy. *Eur Rev Med Pharmacol Sci.* 2016 Jun;20(11):2187-8 IF 1.778

88) Bizzarri M, Cucina A. SMT and TOFT: Why and How They are Opposite and Incompatible Paradigms. *Acta Biotheor.* 2016 , 64(3):221-39 IF 0.646

87) Dinicola S, Fabrizi G, Masiello MG, Proietti S, Palombo A, Minini M, Harrath AH, Alwaseel SH, Ricci G, Catizone A, Cucina A, Bizzarri M. Inositol induces mesenchymal-epithelial reversion in breast cancer cells through cytoskeleton rearrangement. *Exp Cell Res.* 2016 Jul 1;345(1):37-50. DOI: 10.1016/j.yexcr.2016.05.007. IF 3.546

86) Pasta V, Dinicola S, Giuliani A, Harrath AH, Alwaseel SH, Tartaglia F, Cucina A, Bizzarri M. A randomized trial of Boswellia in association with betaine and myo-inositol in the management of breast fibroadenomas. *Eur Rev Med Pharmacol Sci.* 2016 May;20(9):1860-5 IF 1.778

85) Bevilacqua A, Bizzarri M. Physiological role and clinical utility of inositols in polycystic ovary syndrome. *Best Pract Res Clin Obstet Gynaecol.* 2016, 37:129-139. IF 0.94

84) Pasta V, Dinicola S, Giuliani A, Harrath AH, Alwaseel SH, Tartaglia F, Cucina A, Bizzarri M. A Randomized Pilot Study of Inositol in Association with Betaine and Boswellia in the Management of Mastalgia and Benign Breast Lump in Premenopausal Women. *Breast Cancer (Auckl).* 2016 Apr 20;10:37-43. IF 2,38

83) Bizzarri M, Cucina A, Dinicola S, Harrath AH, Alwaseel SH, Unfer V, Bevilacqua A. Does myo-inositol effect on PCOS follicles involve cytoskeleton regulation? *Med Hypotheses.* 2016 Jun;91:1-5. IF 1.066

82) Dinicola S, Pasqualato A, Proietti S, Masiello MG, Palombo A, Coluccia P, Canipari R, Catizone A, Ricci G, Harrath AH, Alwaseel SH, Cucina A, Bizzarri M. Paradoxical E-cadherin increase in 5FU-resistant colon cancer is unaffected during mesenchymal-epithelial reversion induced by γ -secretase inhibition. *Life Sci.* 2016 ;145:174-183. doi: 10.1016/j.lfs.2015.12.048 IF 2.936

2015

81) Dinicola S, Pasta V, Costantino D, Guaraldi C, Bizzarri M. Hyaluronic acid and vitamins are effective in reducing vaginal atrophy in women receiving radiotherapy. *Minerva Ginecol.* 2015 Dec;67(6):523-31. IF 1.07

80) Bizzarri M., Palombo A. Recognizing the "Patient's Phenotype" through Systems Biology. *Curr Synthetic Sys Biol* 2015, 3:1. <http://dx.doi.org/10.4172/2332-0737.1000e114>

79) V. Pasta, G. Gullo, A. Giuliani, A.H. Harrath, S.H. Alwaseel, F. Tartaglia, A. Cucina, M. Bizzarri. An association of boswellia, betaine and myo-inositol (eumastós®) in the treatment of mammographic breast density: a randomized, double-blind study. *European rev med pharmacol sci*, 2015, 19(22):4419-26 doi.org/10.4172/2161-1017.1000136 IF 1.575

78) Facchinetti F, Bizzarri M, Benvenga S, D'Anna R, Lanzone A, Soulage C, Di Renzo GC, Hod M, Cavalli P, Chiu TT, Kamenov ZA, Bevilacqua A, Carlomagno G, Gerli S, Oliva MM, Devroey P. Results from the International Consensus Conference on Myo-inositol and d-chiro-inositol in Obstetrics and Gynecology: the link between metabolic syndrome and PCOS. *Eur J Obstet Gynecol Reprod Biol.* 2015 ; 195:72-76. PMID: 26479434. IF 1.18

77) D Ranieri, A Cucina, M Bizzarri, M Alimandi, MR Torrissi. Microgravity influences circadian clock oscillation in human keratinocytes. *FEBS Open Bio*, 2015. doi:10.1016/j.fob.2015.08.012 IF 2.01

76) Bizzarri M, Monici M, van Loon JJ. How microgravity affects the biology of living systems. *Biomed Res Int.* ;2015:863075 IF 2,134

75) Stornio A, Raciti M, Cucina A, Bizzarri M, Di Renzo L. Quercetin affects Hsp70/IRE1 α mediated protection from death induced by endoplasmic reticulum stress. *Oxid Med Cell Longev.* 2015: 645157 IF 4.492

74) Dinicola S, Masiello MG, Proietti S, Coluccia P, Fabrizi G, Palombo A, Micciulla F, Bistarelli S, Ricci G, Catizone A, De Toma G, Bizzarri M, Bellucci S, Cucina A. Multiwalled carbon nanotube buckypaper induces cell cycle arrest and

apoptosis in human leukemia cell lines through modulation of AKT and MAPK signaling pathways. *Toxicol In Vitro*. 2015, 18;29(7):1298-1308 IF 5.982

73) Ranieri D, Avitabile D, Shiota M, Yokomizo A, Naito S, Bizzarri M, Torrisi MR. Nuclear redox imbalance affects circadian oscillation in HaCaT keratinocytes. *Int J Biochem Cell Biol*. 2015 , 65:113-24 IF 3,905

72) Bevilacqua A, Carlomagno G, Gerli S, Montanino Oliva M, Devroey P, Lanzone A, Soulange C, Facchinetti F, Carlo Di Renzo G, Bizzarri M, Hod M, Cavalli P, D'Anna R, Benvenga S, Chiu TT, Kamenov ZA. Results from the International Consensus Conference on myo-inositol and D-chiro-inositol in Obstetrics and Gynecology - assisted reproduction technology. *Gynecol Endocrinol*. 2015 2:1-6 IF 1,413

2014

71) Unfer V, Proietti S, Gullo G, Porcaro G, Carlomagno G, Bizzarri M. Polycystic Ovary Syndrome: Features, Diagnostic Criteria and Treatments. *Endocrinol Metab Syndr*. 2014, 3: 136. doi:10.4172/2161-1017.1000136 IF 2.7

70) S Dinicola, A Cucina, D Antonacci, M Bizzarri. Anticancer effects of grape seed extract on human cancers: a review. *Journal of Carcinogenesis & Mutagenesis*, 2014, S8:005 IF 2.0

69) Bizzarri M., Cucina A., Palombo A., Masiello M.G. Gravity sensing by cells: mechanisms and theoretical grounds. *Rend. Fis. Acc. Lincei*, 2014, 25: 29-38. IF 0,750

68) F. Testa, A. Palombo, S. Dinicola, F. D'Anselmi, S. Proietti, A. Pasqualato, M.G. Masiello, P. Coluccia, A. Cucina, M. Bizzarri. Fractal analysis of shape changes in murine osteoblasts cultured under simulated microgravity. *Rend. Fis. Acc. Lincei*, 2014, 25:39-47 IF 0,750

67) Aragona C, Galli L, Passaro D, Linari A, Bezerra Espinola MS, Micara G, Tranquilli D, Boninsegna C, Bizzarri M. Morphological and mathematical analysis of icsi embryo shapes and developmental fate: preliminary observations. *The egyptian journal of fertility and sterility*, 2014, 18: 45-51, ISSN: 1110-6352

66) Saggio G., Bizzarri M. Feasibility of teleoperations with multi-fingered robotic hand for safe extravehicular manipulations. *AEROSPACE SCIENCE AND TECHNOLOGY*, 2014, 39: 666-674, ISSN: 1270-9638, doi: 10.1016/j.ast.2014.05.018 IF 1.68

65) Bizzarri M Systems Biology and Microgravity Effects on Living Organisms *Curr Synthetic Sys Biol* 2014, 2:3

64) M Bizzarri, A Cucina, S Proietti The tumor microenvironment as a target for anticancer treatment *Oncobiology and Targets*, 2014 1:3-11.

63) Avitabile D, Ranieri D, Nicolussi A, D'Inzeo S, Capriotti AL, Genovese L, Proietti S, Cucina A, Coppa A, Samperi R, Bizzarri M, Laganà A, Torrisi MR. Peroxiredoxin 2 nuclear levels are regulated by circadian clock synchronization in human keratinocytes. *Int J Biochem Cell Biol*. 2014, 53:24-34. IF 4.046

62) Proietti S, Cucina A, Dobrowolny G, D'Anselmi F, Dinicola S, Masiello MG, Pasqualato A, Palombo A, Morini V, Reiter RJ, Bizzarri M Melatonin down-regulates MDM2 gene expression and enhances p53 acetylation in MCF-7 cells. *J Pineal Res*. 2014 , 57(1):120-9 IF 9.60

61) Bizzarri M, Carlomagno G. Inositol: history of an effective therapy for Polycystic Ovary Syndrome. *Eur Rev Med Pharmacol Sci*. 2014 , 18(13):1896-903 IF 1.76

60) Bizzarri M, Cucina A. Tumor and the microenvironment: a chance to reframe the paradigm of carcinogenesis? *Biomed Res Int*. 2014 :934038 IF 1.579

59) Dinicola S, Chiu TT, Unfer V, Carlomagno G, Bizzarri M. The rationale of the myo-inositol and D-chiro-inositol combined treatment for polycystic ovary syndrome. *J Clin Pharmacol*. 2014 ;54(10):1079-92 IF 2,966

58) Proietti S, Carlomagno G, Dinicola S, Bizzarri M. Soft gel capsules improve melatonin's bioavailability in humans. *Expert Opin Drug Metab Toxicol.* 2014, 10(9):1193-8 IF 2,831

57) Masiello MG, Cucina A, Proietti S, Palombo A, Coluccia P, D'Anselmi F, Dinicola S, Pasqualato A, Morini V, Bizzarri M. Phenotypic switch induced by simulated microgravity on MDA-MB-231 breast cancer cells. *Biomed Res Int.* 2014; 2014:652434 IF 1.579

56) Pisanu ME, Noto A, De Vitis C, Masiello MG, Coluccia P, Proietti S, Giovagnoli MR, Ricci A, Giarnieri E, Cucina A, Ciliberto G, Bizzarri M, Mancini R. Lung cancer stem cell lose their stemness default state after exposure to microgravity. *Biomed Res Int.* 2014; 2014:470253 IF 1.579

55) Dinicola S, Pasqualato A, Cucina A, Coluccia P, Ferranti F, Canipari R, Catizone A, Proietti S, D'Anselmi F, Ricci G, Palombo A, Bizzarri M. Grape seed extract suppresses MDA-MB231 breast cancer cell migration and invasion. *Eur J Nutr.* 2014 PMID: 23754570 DOI: 10.1007/s00394-013-0542-6 IF 3.467

2013

54) D'Anselmi F, Masiello MG, Cucina A, Proietti S, Dinicola S, Pasqualato A, Ricci G, Dobrowolny G, Catizone A, Palombo A, Bizzarri M. Microenvironment promotes tumor cell reprogramming in human breast cancer cell lines. *PLoS One.* 2013; 8(12):e83770 IF 3.534

53) Santonico M, Pennazza G, Grasso S, D'Amico A, Bizzarri M. Design and test of a biosensor-based multisensorial system: a proof of concept study. *Sensors (Basel).* 2013 Dec 4;13(12):16625-40. PMID: 24304640 PMCID: PMC3892864 DOI: 10.3390/s131216625. IF. 2.048

52) Tafani M, Perrone GA, Pucci B, Russo A, Bizzarri M, Mechanick J, Carpi A, Russo MA. Reprogramming Cancer Cells in Endocrine-Related Tumors: Open Issues. *Curr Med Chem.* 2013 IF 3,715

51) Tafani M, De Santis E, Coppola L, Perrone GA, Carnevale I, Russo A, Pucci B, Carpi A, Bizzarri M, Russo MA. Bridging hypoxia, inflammation and estrogen receptors in thyroid cancer progression. *Biomed Pharmacother.* 2013 IF 2,108

50) Bizzarri M. Systems Biology for Understanding Cancer Biology *Curr Synthetic Sys Biol* 2013, 2:2

49) Pasqualato A, Lei V, Cucina A, Dinicola S, D'Anselmi F, Proietti S, Masiello MG, Palombo A, Bizzarri M. Shape in migration: Quantitative image analysis of migrating chemoresistant HCT-8 colon cancer cells. *Cell Adh Migr.* 2013 Sep 1;7(5):450-9. DOI: 10.4161/cam.26765. IF 3.395

48) Ferranti F, D'Anselmi F, Caruso M, Lei V, Dinicola S, Pasqualato A, Cucina A, Palombo A, Ricci G, Catizone A, Bizzarri M. TCam-2 seminoma cells exposed to egg-derived microenvironment modify their shape, adhesive pattern and migratory behaviour: a molecular and morphometric analysis. *PLoS One.* 2013 Oct 1;8(10):e76192 IF 3.534

47) Dinicola S, Morini V, Coluccia P, Proietti S, D'Anselmi F, Pasqualato A, Masiello MG, Palombo A, De Toma G, Bizzarri M, Cucina A. Nicotine increases survival in human colon cancer cells treated with chemotherapeutic drugs. *Toxicol In Vitro.* 2013 Dec;27(8):2256-63 IF 3.207

46) Bizzarri M, Proietti S, Cucina A, Reiter RJ. Molecular mechanisms of the pro-apoptotic actions of melatonin in cancer: a review. *Expert Opin Ther Targets.* 2013 Dec;17(12):1483-96 IF 4.901

45) Pisani A, Sabbatini M, Riccio E, Rossano R, Andreucci M, Capasso C, De Luca V, Carginale V, Bizzarri M, Borrelli A, Schiattarella A, Santangelo M, Mancini A. Effect of a recombinant manganese superoxide dismutase on prevention of contrast-induced acute kidney injury. *Clin Exp Nephrol.* 2013 Jun 27 IF 1,708

44) Bizzarri M, Palombo A, Cucina A. Theoretical aspects of Systems Biology. *Prog Biophys Mol Biol.* 2013, 112(1-2):33-43. DOI: 10.1016/j.pbiomolbio.2013.03.019 . IF. 3.377

43) Dinicola S, Marigiò MA, Morabito C, Guarneri S, Cucina A, Pasqualato A, D'Anselmi F, Proietti S, Coluccia P, Bizzarri M. Grape seed extract triggers apoptosis in Caco-2 human colon cancer cells through reactive oxygen species and calcium increase: extracellular signal-regulated kinase involvement. *Br J Nutr.* 2013, 110(5): 797-809. DOI: 10.1017/S0007114510001522. IF 3.342

42) Pasta V, Amabile MI, Bizzarri M, Monti M. Breast sarcoma in a pregnant patient A case report. *Ann Ital Chir.* 2013 IF 0,683

41) Proietti S., Cucina A., Reiter RJ, Bizzarri M., Molecular Mechanisms of Melatonin's inhibitory actions on Breast Cancers. *Cell Mol Life Sci.* 2013, 70(12): 2139-2157 IF 5.856

40) Bizzarri M., Pasqualato A., Cucina A., Pasta V. Physical forces and non linear dynamics mould fractal cell shape *Histol Histopathol.* 2013, 28(2):155-174. IF 2,236

39) Bizzarri M., Saggese E. Human space flights: facts and dreams. *Ann. Kinesiol.* 2013, 2: 103-116.

2012

38) Cucina A, Dinicola S, Coluccia P, Proietti S, D'Anselmi F, Pasqualato A, Bizzarri M. Nicotine stimulates proliferation and inhibits apoptosis in colon cancer cell lines through activation of survival pathways. *J Surg Res.* 2012 Mar 10. PMID:22520577. IF 2,018

37) Pasqualato A, Palombo A, Cucina A, Marigiò MA, Galli L, Passaro D, Dinicola S, Proietti S, D'Anselmi F, Coluccia P, Bizzarri M. Quantitative shape analysis of chemoresistant colon cancer cells : correlation between morphotype and phenotype. *Exp Cell Res.* 2012; 318(7):835-46. PMID: 22342954 IF 3,557

36) Dinicola S, Cucina A, Pasqualato A, D'Anselmi F, Proietti S, Lisi E, Pasqua G, Antonacci D, Bizzarri M. Antiproliferative and Apoptotic Effects Triggered by Grape Seed Extract (GSE) versus Epigallocatechin and Procyanidins on Colon Cancer Cell Lines. *Int J Mol Sci.* 2012;13(1):651-664. PMID:22312277 IF 2,464

2011

35) Anna Laura Capriotti, Giuseppe Caruso, Chiara Cavaliere, Patrizia Foglia, Mariano Bizzarri, Aldo Laganà. Rapid Resolution Liquid chromatography/High Resolution Tandem Mass Spectrometry to Characterize Metabolic Changes in Subjects Involved in MARS500 Project. *Chromatographia* 2011, 73 (suppl. 1): 45-53, DOI: 10.1007/s10337-010-1880-7 IF 1,195

34) Bizzarri M, Giuliani A, Cucina A, D'Anselmi F, Soto AM, Sonnenschein C. Fractal analysis in a systems biology approach to cancer. *Semin Cancer Biol.* 2011, 21(3):175-82. doi: 10.1016/j.semcancer.2011.04.002. PMID: 21514387 IF 6.475

33) Dinicola S, D'Anselmi F, Pasqualato A, Proietti S, Lisi E, Cucina A, Bizzarri M. A systems biology approach to cancer: fractals, attractors, and nonlinear dynamics. *OMICS.* 2011, 15(3):93-104. PMID: 21319994 IF 2,441

32) Proietti S, Cucina A, D'Anselmi F, Dinicola S, Pasqualato A, Lisi E, Bizzarri M. Melatonin and vitamin D3 synergistically down-regulate Akt and MDM2 leading to TGFβ-1-dependent growth inhibition of breast cancer cells. *J Pineal Res.* 2011, 50(2):150-8. doi: 10.1111/j.1600-079X.2010.00824.x. PMID: 21091766 IF 5.794

31) Bizzarri M, Cucina A, Biava PM, Proietti S, D'Anselmi F, Dinicola S, Pasqualato A, Lisi E. Embryonic morphogenetic field induces phenotypic reversion in cancer cells. Review article. *Curr Pharm Biotechnol.* 2011, 12(2):243-53. PMID: 21044001 IF 2,805

30) D'Anselmi F, Cucina A, Biava PM, Proietti S, Coluccia P, Frati L, Bizzarri M. Zebrafish stem cell differentiation stage factors suppress Bcl-xL release and enhance 5-Fu-mediated apoptosis in colon cancer cells. *Curr Pharm Biotechnol.* 2011 , 12(2):261-7. PMID: 21043999 IF 2,805

29) D'Anselmi F, Valerio M, Cucina A, Galli L, Proietti S, Dinicola S, Pasqualato A, Manetti C, Ricci G, Giuliani A, Bizzarri M. Metabolism and cell shape in cancer: a fractal analysis. *Int J Biochem Cell Biol.* 2011 , 43(7):1052-8. PMID: 20460170. DOI: 10.1016/j.biocel.2010.05.002. IF 4,634

2010

28) Dinicola S, Cucina A, Pasqualato A, Proietti S, D'Anselmi F, Pasqua G, Santamaria AR, Coluccia P, Laganà A, Antonacci D, Giuliani A, Bizzarri M. Apoptosis-inducing factor and caspase-dependent apoptotic pathways triggered by different grape seed extracts on human colon cancer cell line Caco-2. *Br J Nutr.* 2010, 104(6):824-32. PMID:20540818 IF 3,072

27) Morabito C, Rovetta F, Bizzarri M, Mazzoleni G, Fanò G, Marigiò MA. Modulation of redox status and calcium handling by extremely low frequency electromagnetic fields in C2C12 muscle cells: A real-time, single-cell approach. *Free Radic Biol Med.* 2010 , 48(4):579-89. PMID: 20005945 IF 5,707

2009

26) Valerio M, Panebianco V, Sciarra A, Osimani M, Salsiccia S, Casciani L, Giuliani A, Bizzarri M, Di Silverio F, Passariello R, Conti F. Classification of prostatic diseases by means of multivariate analysis on in vivo proton MRSI and DCE-MRI data. *NMR Biomed.* 2009 , 22(10):1036-46. PMID: 19579258 IF 3,790

25) Cucina A, Proietti S, D'Anselmi F, Coluccia P, Dinicola S, Frati L, Bizzarri M. Evidence for a biphasic apoptotic pathway induced by melatonin in MCF-7 breast cancer cells. *J Pineal Res.* 2009, 46(2):172-80.. PMID: 19175854 IF 5.209

2008

24) Bizzarri M. Consequences of space exploration for mankind *G Ital Nefrol.* 2008 , 25(6):686-9. PMID: 19048568 IF 0,59

23) Bizzarri M, Cavaliere C, Foglia P, Guarino C, Samperi R, Laganà A. A label-free method based on MALDI-TOF mass spectrometry for the absolute quantitation of troponin T in mouse cardiac tissue. *Anal Bioanal Chem.* 2008 , 391(5):1969-76. PMID:18421442 IF 3,286

22) Bizzarri M, Cucina A, Conti F, D'Anselmi F. Beyond the oncogene paradigm: understanding complexity in cancerogenesis. *Acta Biotheor.* 2008 , 56(3):173-96. PMID: 18288572 IF 0.735

21) D'Anselmi F, Cucina A, Cavallaro G, Bizzarri M, Cavallaro RA, Fuso A, Cavallaro A, Scarpa S. S-adenosylmethionine inhibits ubiquitin-proteasome system in vitro and on rat vascular smooth muscle cells. *Protein Pept Lett.* 2008, 15(1):58-62. PMID: 18221015 IF 1.281

2006

20) Miccheli AT, Miccheli A, Di Clemente R, Valerio M, Coluccia P, Bizzarri M, Conti F. NMR-based metabolic profiling of human hepatoma cells in relation to cell growth by culture media analysis. *Biochim Biophys Acta.* 2006, 1760 (11):1723-31. PMID: 17052856 IF 4,12

19) Cucina A, Biava PM, D'Anselmi F, Coluccia P, Conti F, di Clemente R, Miccheli A, Frati L, Gulino A, Bizzarri M. Zebrafish embryo proteins induce apoptosis in human colon cancer cells (Caco2). *Apoptosis*. 2006 , 11(9):1617-28. PMID: 16820966 IF 3.421

2005

18) Livraghi, T., Meloni, F., Frosi, A., Lazzaroni, S., Bizzarri M., Frati, L., Biava, P.M. Treatment with stem cell differentiation stage factor of intermediate-advanced hepatocellular carcinoma: an open randomised clinical trial *Oncol. Res*. 2005, 15: 399-408. DOI: 10.3727/096504005776449716. PMID: 16491958 IF 0,82

17) Franchi F, Ielapi T, Bizzarri M, Seminara P. Embryo extracts ootherapy reduces alpha-fetoprotein levels in hepatocellular carcinoma patients. *J Gastroenterol Hepatol*. 2005 , 20(9):1467-8. PMID: 16105144 IF 1,12

2004

16) Manetti C, Bianchetti C, Bizzarri M, Casciani L, Castro C, D'Ascenzo G, Delfini M, Di Cocco ME, Laganà A, Miccheli A, Motto M, Conti F. NMR-based metabonomic study of transgenic maize. *Phytochemistry*. 2004 Dec;65(24):3187-98. PMID: 15561185 IF 2,00

2003

15) Bizzarri M, Cucina A, Valente MG, Tagliaferri F, Borrelli V, Stipa F, Cavallaro A.. Melatonin and vitamin D3 increase TGF-beta1 release and induce growth inhibition in breast cancer cell cultures. *J Surg Res*. 2003 , 110 (2):332-7. PMID: 12788662 IF 1.735

14) M. Bizzarri, R. Facco, A. Laganà, L. Frati. Urinary and plasma Tryptophan (Trp) and cocancerogenic Trp-metabolites of the Nicotinic-acid pathway in Bladder cancer Patients. *J Tumor Markers Oncol*, 2003, 18(2) 141- 152. ISSN 0886-3849 IF 0,18

2002

13) Bizzarri M, Filippo R, Valente MG, Bernardeschi D, Ronchetti F, Monini S, Chiappini I, Barbara M. Release of transforming growth factor beta-1 in a vestibular schwannoma cell line. *Acta Otolaryngol*. 2002 , 122 (7):785-7. PMID: 12484657 IF 0,729

12) M. Bizzarri, R. Facco, T. Ielapi and L. Frati
The embryonic and maternal regulatory factor as a palliative Therapy for Advanced Solid Tumors
J. Tumor Marker Onc., 2002, 2(17): 71-76 ISSN 0886-3849 IF 0,18

11) P.M. Biava, Bonsignorio D., M. Hoxha, M. Impagliazzo, R. Facco, T. Ielapi, L. Frati, M. Bizzarri. Post-traslational Modifications of the Retinoblastoma Protein (pRB) induced by in vitro administraton of Zebrafish Embryonic extracts on Human Kidney Carcinoma. *J. Tumor Marker Onc.* 2002, 2(17): 59-64 ISSN 0886-3849 IF 0,18

<2000

10) M. Bizzarri. Neurobiology and Quantum Electro Dynamic (QED) Coherence of Mental States. *Rivista di Biologia/ Biology Forum*. 2000, 93(3): 495-500. ISSN: 00356050 IF 0,14

- 9) Laganà A, Pardo-Martinez B, Marino A, Fago G, Bizzarri M. Determination of serum total lipid and free N-acetylneuraminic acid in genitourinary malignancies by fluorimetric high performance liquid chromatography. Relevance of free N-acetylneuraminic acid as tumour marker. *Clin Chim Acta*. 1995, 243 (2):165-79. PMID: 8747492 IF 1,00
- 8) Lagana A, Martinez BP, Marino A, Fago G, Bizzarri M. Correlation of serum sialic acid fractions as markers for carcinoma of the uterine cervix. *Anticancer Res*. 1995, 15(5B):2341-6. PMID: 8572649 IF 1,38
- 7) A. Lagana, A. Marino, G. Fago, B. Pardo-Martinez, M. Bizzarri. Sensitive assay for melatonin in human serum by liquid chromatography. *Anal. Chim. Acta*, 1995, 316: 377–385 doi: 10.1016/0003-2670(95)00298-E IF 1.8
- 6) A. Bertuzzi, A. de Santis, A. Gandolfi, M. Bizzarri Excretion of Tryptophan by human kidney: mathematical model and parameter estimation. *Systems Analysis Modelling Simulation SAMS*, 1993, 12: 1-9 ISSN:0232-9298
- 5) Lagana A, Bizzarri M, Marino A, Mancini M. Solid phase extraction and high-performance liquid chromatographic determination of doxophylline in plasma. *Biomed Chromatogr*. 1990, 4 (5):205-7. PMID: 2279147 IF 1,17
- 4) Bizzarri M, Catizone A, Pompei M, Chiappini L, Curini L, Lagana A. Determination of urinary tryptophan and its metabolites along the nicotinic acid pathway by high performance liquid chromatography with ultraviolet detection. *Biomed Chromatogr*. 1990, 4 (1):24-7. PMID: 2310838 IF 1,17
- 3) M. Bizzarri et al. (Italian Multicenter Cooperative Group). A double-blind randomized study comparing intramuscular granisetron with i.m. granisetron plus dexamethasone in the prevention of delayed emesis induced by cisplatin *Anti-Cancer Drugs*, 1999, 10: 465-474 PMID: 10477166 IF 1.2
- 2) Di Silverio F, Bizzarri M, Chiappini L, Ottaviano C, Tenaglia R. Etiology of bladder cancer. *Minerva Med*. 1985, 76(14-15):691-704. PMID: 3991032 IF 1.3
- 1) Il monitoraggio nutrizionale del paziente neoplastico. Bizzarri M., Chiappini L., Cornacchia G., Pompei M. *Giorn. It. Oncol*. 1985, 5(2): 127-140. ISSN: 0392128X

Part XIII – Books

Bizzarri M. *Systems Biology-II. Springer protocols*. Humana press, Springer-Nature, 2023. ISBN-10: 107163576X ISBN-13: 978-1071635766

Bizzarri M., Cacciari M. *Covid-19: un'epidemia da decodificare*. ByoBlu Edizioni, Milano, 2022. ISBN-13: 979-1280657060

Bizzarri M., Angeloni A., Marchese C., Verna R. *Interpretazione clinica degli esami di laboratorio*. 2020. Piccin, Padova. ISBN-10: 8829930938 - ISBN-13: 978-8829930937

Bizzarri M. *Approaching Complex Diseases: Network-Based Pharmacology and Systems Approach in Biomedicine (Human Perspectives in Health Sciences and Technology)*. 2019, Springer-Nature. ISBN-10: 3030328562 ISBN-13: 978-3030328566

Bizzarri M. *Systems Biology. Springer protocols*. Humana press, Springer-Nature, 2018. ISBN-10: 1493984918 -ISBN-13: 978-1493984916

A. Biagini e M. Bizzarri. *Spazio: scenari di cooperazione*, Passigli (Firenze), 2013 ISBN-10: 8836813364 -ISBN-13 : 978-8836813360

A. Biagini e M. Bizzarri. *Spazio: scenari di competizione*, Passigli (Firenze), 2011 - ISBN 978-88-368-1297-4

Bizzarri M. *The New Alchemists: the risk of Genetic Modification*. Wit Press (Boston), 2012. ISBN 978-1-84564-662-2

Bizzarri M. *Quel Gene di troppo*. Editori Riuniti (Eds.) 2008. ISBN 978-88-359-6050-8 (il libro è stato tradotto in spagnolo: *El Imperio de los Genes*, Ed. Seristar, 2010 (Cuba – America Latina).

Bizzarri M. *La Mente e il Cancro*. Milano, Frontiera Ed., 1999. ISBN 88-87216-04-5 (Trad. Portoghese, A Mente e o Cancer, Summus Ed., 2001; ISBN-10 : 8532307582 - ISBN-13 : 978-8532307583)

Bizzarri M. *Le infezioni micotiche nel paziente oncologico*, UTET, Milano, 1998.

Bizzarri M & A. Laganà. *Il Tramonto del Tumore*. Prefazione di U. Veronesi, Errebian Ed. 1991, Roma

Part XIV – Chapters on books

Porcaro G., Bizzarri, M., Monastra, G., Filati, P., Unfer, V. Strategies for the treatment of polycystic ovary syndrome (PCOS) women: The role of myo-inositol (MI) and d-chiro-inositol (DCI) between diet and therapy. in: *Polycystic Ovary Syndrome (PCOS): Clinical Aspects, Potential Complications and Dietary Management*. Nova Science Publishers, Inc., 2017, pag. 59-84. ISBN: 978-163485955-4;978-163485924-0

Mugavero, R., Saggio, G., Sabato, V., Bizzarri, M. The multisensory integrated modules for training. Proceedings - *International Camahan Conference on Security Technology* Volume 2014-October, Issue October, 15 December 2014, Article number 6987011. ISSN: 10716572

Simeoni C, Dinicola S, Cucina A, Mascia C, Bizzarri M. Systems Biology Approach and Mathematical Modeling for Analyzing Phase-Space Switch During Epithelial-Mesenchymal Transition. *Methods Mol Biol*. 2018; 1702:95-123. doi: 10.1007/978-1-4939-7456-6_7 Springer-Nature

Bizzarri M., Cucina A., Palombo A. The conceptual foundations of Systems Biology: an Introduction. In: *Recent Advances in Systems Biology Research*. Valente A.X.C.N., Sarker A. and Gao Y., Editors. , Nova science pub., New York, 2014.

Bizzarri M., Biochimica e Fisiologia dell'Inositolo, in: *Esperienza clinica con inositolo in ginecologia e ostetricia*. F. Facchinetti, Ed. Minerva Medica, 2014, pag. 9-17. ISBN-13 978-88-7711-789-2.

Bizzarri M, Dinicola S., Manetti C. Systems Biology approach to metabolomics in cancer studies. In: *Systems Biology in Cancer Research and Drug Discovery*. Azmi A. Ed. Springer, 2012, ISBN 978-94-007-4818-7.

Bizzarri M. and Giuliani A.

Representing cancer cell trajectories in a phase-space diagram: switching cellular states by biological phase transitions. In: *Applied Statistics for Network Biology: Methods in Systems Biology*. M Dehmer., F. Emmert-Streib, A. Graber, A. Salvador Eds. Wiley Ed. , 2011. DOI: 10.1002/9783527638079.ch17

S. Proietti, A. Cucina, S. Dinicola, A. Pasqualato, F. D'Anselmi and M. Bizzarri.

Molecular and epigenetic effects of Melatonin in Breast Cancer. In: *Melatonin in the Promotion of Health*, R.R. Watson Eds., Taylor & Francis, Tucson, 2010. ISBN 9780849385643

M. Bizzarri, F. D'Anselmi, M. Valerio, A. Cucina, S. Proietti, S. Dinicola, A. Pasqualato, C. Manetti, L. Galli, A. Giuliani
Metabolomic profile and fractal dimensions in breast cancer cells. In: *Metabolomics: Metabolites, Metabolomics and Cancer*, ISBN: 978-1-61668-006-0, Editor: Justin S. Knapp and William L. Cabrera, NovaScience, London, 2010.

Bizzarri M., Dinicola S.

Valore nutrizionale dell'uva da tavola. Bayer Crop Science (Ed.), Milano, 2010, pp. 70-78. ISBN 978-88-96301-09-8

Bizzarri M., Fanò G

L'uomo e Le Onde: Bassa Frequenza. Quaderni Della Società Italiana di Elettromagnetismo, 2008, Vol. 3; pp. 131-152.

Bizzarri M, Cucina A.

Biological effects of cosmic radiation during stratospheric flights. In: *Mem. S.A.It.* Vol. 79, 3 2008

Bizzarri M., Cucina A.

Reversibilità ed irreversibilità della trasformazione neoplastica: ipotesi per un nuovo paradigma. in: *Cancro, complessità e derive psicoanalitiche*. F. Angeli (Eds), Roma 2007, pp. 57-66. ISBN 978-88-464-8331-7.

Bizzarri M.

Limiti della predittività genetica in oncologia. Il paradigma della irreversibilità della malattia neoplastica. In: *La frontiera dell'invisibile*. Baldini Castaldi Dalai (Eds.), Milano, 2005, pp. 175-185. ISBN 88-8490-819-1

Bizzarri M.

Sistemi operativi e stati mentali. L'attivazione del guaritore interno come espressione funzionale di stati. In: *La Mente e il Corpo*. Riza, Milano, 2004, pp. 85-118. ISBN 88-7071-077-7

Bizzarri M .

Neoplasie e prevenzione. In: *Bioetica e cultura della prevenzione*. Apeiron (Ed), Bologna. 2001, pp. 89-114. ISBN 88-87690-06-5

Bizzarri M.

Epidemiologia e multiculturalismo. In: *Medicina e multiculturalismo*, Apeiron (Ed), Bologna. 2000, pp. 155-172. ISBN 88-87690-05-7.

Bertuzzi A., Bizzarri M., De Santis A., Gandolfi A. Parameter estimation by maximum likelihood in a model of Tryptophan renal excretion, in: *Proceedings of 4th International Symposium on Systems Analysis and Simulation*. Berlin, Sydow A. ed., Elsevier Amsterdam, 1992, pp. 275-280.

Experience with Flutamide in advanced prostatic cancer patients refractory to previous endocrine therapy. Di Silverio F., Tenaglia R., Bizzarri M., Bigio A., Saragnano R. *J Drug Dev.* 1987, 1(1): 10-16 ISSN 0267-5323

Di Silverio F., Bizzarri M.

Eziopatogenesi del carcinoma vescicole. In: *Il Medico del Lavoro oggi*. Acta Medica, Roma. 1985 ISBN 88-375-0006-8

Rocchini P., Bizzarri M., Fagioli A., Di Silverio F.

Urinary and plasma levels of Trp and related metabolites in bladder cancer patients in: *Advances in Urological Oncology and Endocrinology*, Acta Medica, Roma, 1984, pp. 391-398. ISBN 88-375 0003 – 5

Di Silverio F., Tenaglia R., Ferraro F., D'Eramo G., Bizzarri M., Concolino G., Scarpa R. , Usai E. Flutamide in advanced prostatic cancer. in: *Advances in Urological Oncology and Endocrinology*, Acta Medica, Roma, 1984, pp. 427-432. ISBN 88-375 0003 – 5

Il sottoscritto, a conoscenza di quanto prescritto dall'art. 76 del D.P.R. 28 dicembre 2000 n. 445, sulla responsabilità penale cui può andare incontro in caso di falsità in atti e di dichiarazioni mendaci, nonché di quanto prescritto dall'art. 75 del D.P.R. 28 dicembre 2000 n. 445, sulla decadenza dai benefici eventualmente conseguenti al provvedimento emanato sulla base di dichiarazioni non veritiere, ai sensi e per gli effetti del citato D.P.R. n. 445/2000 e sotto la propria personale responsabilità dichiara che tutte le informazioni contenute nel proprio curriculum vitae sono veritiere.

Autorizza inoltre al trattamento dei dati personali, secondo quanto previsto dalla Legge 196/03 art. 7 e 13 -30/06/2003.

Roma 27/07/2024 Firma

Mariano Bizzarri

A handwritten signature in black ink, appearing to read 'Mariano Bizzarri', written in a cursive style.